G1 Therapeutics CONFIDENTIAL  
  
   
 
  
Phase 1b/2 Safet y, Pharmacokinetic, and Efficacy  Study of G1T38 in Combination with 
Osimertinib in Patients with EGFR Mutation -Positive Metastatic  Non -Small Cell Lung 
Cancer (NSCLC)  
  
Clinical Study Protocol G1T38-[ADDRESS_797465] #: 2017-004315-39 
  
Version 4.0 Issue Date: 02September 2019 
 
Investigational Phase: 1b/2  
 
Sponsored by: 
G1 Therapeutics 
[ADDRESS_797466] 
Research Triangle Park, NC [ZIP_CODE]  
 
 
 
 
 
THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET 
INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE 
LICENSING AND/OR REGISTRATION OF PRODUCTS FOR G1 THERAPEUTICS .  
THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED,  IN WHOLE OR IN 
PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF 
G1 THERAPEUTICS . 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 3 of 103   
G1 Therapeutics CONFIDENTIAL  PROTOCOL SIGNATURE [CONTACT_89840] G1T38-03: Phase 1b/2 Safet y, Pharmacokinetic, and Efficacy 
Study of G1T38 in Combination with Osimertinib in Patients with EGFR  Mutation- Positive 
Metastatic Non-Small Cell Lung Cance r (NSCLC)   
Protocol Version 4.0 Issue Date: 02 September  2019 
By [CONTACT_31300], the investigator agrees to adhere to the protocol as outlined. 
Principal Investigator:   
 
[INVESTIGATOR_89763]  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 5 of 103   
G1 Therapeutics CONFIDENTIAL  8.3. Dose, Dosing Regimen, and Route  ................................................................................................ . 42 
8.3.1.  G1T38 ...........................................................................................................................  42 
8.3.2.  Osimertinib  ....................................................................................................................  42 
8.3.3.   ......................................................................................................................................  43 
[IP_ADDRESS].  G1T38 ......................................................................................................  43 
[IP_ADDRESS].  Osimertinib  ..............................................................................................  [ADDRESS_797467]- Treatment Visit/Early Termination  .........................................................................................  60 
9.4. Survival Follow -up Phase  ...............................................................................................................  60 
9.5. Unscheduled Visits  .........................................................................................................................  60 
10. STUDY PROCEDURES AND ASSESSMENTS .......................................................................................  61 
10.1.  Efficacy Assessments  ......................................................................................................................  61 
10.1.1.  Tumor Lesions: Identification and Follow -up ...............................................................  62 
[IP_ADDRESS].  Measurable Lesions  .................................................................................  62 
[IP_ADDRESS].  Nonmeasurable Lesions  ...........................................................................  63 
[IP_ADDRESS].  New Lesions  ............................................................................................  63 
10.1.2.  Definitions of Tumor Response and Disease Progression .............................................  63 
[IP_ADDRESS].  Evaluation of Target Lesion Response  ....................................................  63 
[IP_ADDRESS].  Evaluation of Nontarget Lesions  ..............................................................  64 
[IP_ADDRESS].  Evaluation of Overall Response at Each Time Point  ...............................  64 
10.2.  Cell- Free DNA  ................................................................................................................................  65 
10.3.  Archival Tumor Tissue  ...................................................................................................................  65 
10.4.  Optional Tumor Biopsy at Time of Disease Progression  ................................................................  65 
10.5.  Pharmacokinetic Assessments  ........................................................................................................  66 
10.5.1.  Pharmacokinetic Sampling ............................................................................................  66 
10.5.2.  Pharmacokinetic Parameters  .........................................................................................  67 
10.6.  Safety Assessments  .........................................................................................................................  68 
10.6.1.  Adverse Events and Serious Adverse Events  ................................................................  68 
[IP_ADDRESS].  Definition of Adverse Event ....................................................................  69 
[IP_ADDRESS].  Definition of Serious Adverse Event  .......................................................  70 
[IP_ADDRESS].  Assessment of the Severity of Adverse Events  ........................................  72 
[IP_ADDRESS].  Assessment of the Causal Relationship of Adverse 
Events to Study Drug  ...............................................................................  72 
[IP_ADDRESS].  Assessment of the Outcome of A dverse Events  .......................................  72 
[IP_ADDRESS].  Method, Frequency, and Time Period for Detecting Adverse Events and Serious Adverse Events  ...........................................  73
 
[IP_ADDRESS].  Documentation of Adverse Events and Serious Adverse Events  ......................................................................................................  73
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 6 of 103   
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS].  Adverse Event Coding  .............................................................................  73 
[IP_ADDRESS].  Reporting of Serious Adverse Events  ......................................................  73 
[IP_ADDRESS].  Follow -up of Adverse Events .................................................................. 74 
[IP_ADDRESS].  Regulatory Aspects of Adverse Event Reporting  ....................................  74 
[IP_ADDRESS].  Handling of Overdose  ..............................................................................  75 
[IP_ADDRESS].  Reporting of Pregnancies  .........................................................................  75 
10.6.2.  Clinical Laboratory Assessments  ..................................................................................  76 
10.6.3.  Demographics and Vital Signs  ......................................................................................  78 
10.6.4.  Physical Examination  ....................................................................................................  78 
10.6.5.  Electrocardiogram Assessments  ....................................................................................  78 
10.6.6.  Ophthalmic Examination ...............................................................................................  79 
10.6.7.  Echocardiogram/MUGA ...............................................................................................  79 
10.7.  Biomarker Analysis .........................................................................................................................  80 
10.8.  Appropriateness of Measurements  .................................................................................................. 80 
11. STUDY TERMINATION OR  STUDY DRUG DISCONTIN UATION .....................................................  81 
11.1.  Study Termination ...........................................................................................................................  81 
11.2.  Site Termination  ..............................................................................................................................  81 
11.3.  Discontinuation of Study Drug .......................................................................................................  81 
11.4.  Withdrawal of Patients from the Study  ...........................................................................................  82 
12. STATISTICS  ...............................................................................................................................................  83 
12.1.  Sample Size and Power ...................................................................................................................  83 
12.2.  General Considerations  ...................................................................................................................  83 
12.2.1.  Analysis Populations  .....................................................................................................  83 
12.2.2.  Timing of Analyses .......................................................................................................  84 
[IP_ADDRESS].  Interim Safety Reviews  ............................................................................  84 
[IP_ADDRESS].  Independent Data Monitoring Committee  ...............................................  84 
[IP_ADDRESS].  Final Analysis  ..........................................................................................  84 
[IP_ADDRESS].  End of Study Analysis  .............................................................................  84 
12.2.3.  General Considerations for Data Analysis  ....................................................................  84 
12.3.  Part 1 (Phase 1b) Statistical Analyses .............................................................................  [ADDRESS_797468] Statement  ..............................................................................................................  93 
14.2.  Independent Ethics Committee/Institutional Review Board  ...........................................................  [ADDRESS_797469] KEEPI[INVESTIGATOR_1645]  ........................................................................................  95 
15.1.  Data Collection and Retrieval  .........................................................................................................  95 
15.2.  Investigator Reporting Req uirements ..............................................................................................  95 
15.3.  Records Retention  ...........................................................................................................................  95 
15.4.  Study Monitoring  ............................................................................................................................  96 
15.5.  Audits and Inspections  ....................................................................................................................  96 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 7 of 103   
G1 Therapeutics CONFIDENTIAL  16. PUBLICATION POLICY  ...........................................................................................................................  97 
17. REFERENCES ............................................................................................................................................  98 
18. APPENDICES  ...........................................................................................................................................  100 
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797470] of In -Text Tables 
Table 4 -1 Summary of G1T38 -Related Adverse Events by [CONTACT_602399] G1T38 -02 (as of 
[ADDRESS_797471]  2017)  ............................................................................................................  25 
Table 4 -2 Osimertinib and G1T38: Potential Risks for Drug -Drug 
Interactions and Mitigating Data  ...................................................................................  28 
Table 5 -1 Study Objectives  ...........................................................................................................  31 
Table  6-1 Projected G1T38 Dose Levels, Part 1  ...........................................................................  33 
Table 8 -1 G1T38  Dose Level  Adjustments  Based on G1T38- related 
Hematologic Toxicities  ................................................................................................ . 43 
Table  8-2 Recommended Dose Modifications for Osimertinib- Related 
Adverse Reactions  .........................................................................................................  45 
Table  9-1 Schedule of Assessments for Part 1  ..............................................................................  54 
Table  9-2 Schedule of Assess ments for Part 2  ..............................................................................  57 
Table 10 -1 Evaluation of Overall Response at Each Time Point for Patients 
with Target Lesions  .......................................................................................................  65 
Table  10-2 Part 1: Cycle [ADDRESS_797472] of In -Text Figures  
Figure 8 -1 Study Schema: Part 1  ....................................................................................................  40 
Figure 8 -2 Study Schema: P art 2 ....................................................................................................  41 
Figure 12 -1 Categories of Source Data for Patients  ..........................................................................  88 
 
 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797473] overall response  
CBC complete blood count  
CBR clinical benefit rate  
CDK4/6  cyclin -dependent kinase 4/6  
cfDNA  cell-free DNA  
CFR Code of Federal Regulations 
CI confidence interval  
CL/F  apparent oral clearance  
CLIA  Clinical Laboratory Improvement Amendments 
Cmax maximum concentration  
CNS  central nervous system 
CR complete response  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CV coefficient of variation  
CYP  cytochrome P450  
DDI drug-drug interaction  
DLT dose-limiting toxicity  
EC 50 50% effective concentration  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EGFR epi[INVESTIGATOR_602387] 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 10 of 103  
G1 Therapeutics CONFIDENTIAL  Abbreviation  Definition  
FDG -PET positron emission tomography with 2 -deoxy -2-[fluorine -18]fluoro -D-glucose  
FGFR  fibroblast growth factor receptor 
FIH first-in-human 
G1 gap [ADDRESS_797474]  high-resolution computed tomography  
IB Investigator’s Brochure  
IC50 50% inhibitory concentration  
ICH International Council for Harmonisation  
IDMC  independent data monitoring committee  
IEC independent ethics committee  
IGF1R  insulin -like growth factor [ADDRESS_797475] diameter  
LVEF left ventricular ejection fraction  
MATE1 or 2-K multidrug and toxin extrusion 1 or 2- K  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
MTD maximum tolerated dose  
MUGA  multigated acquisition  
NCI National Cancer Institute 
NE not evaluable  
NSCLC  non-small cell  lung cancer  
NTL nontarget lesion  
NYHA [LOCATION_001] Heart Association  
OCT1 or 2  organic cation transporter 1 or 2 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 11 of 103  
G1 Therapeutics CONFIDENTIAL  Abbreviation  Definition  
ORR overall response rate  
OS overall survival  
PD progressive disease 
PET positron emission tomography 
PFS progression -free survival  
P-gp P-glycoprotein  
PK pharmacokinetic(s)  
PP per protocol  
PR partial response  
PTV Post- Treatment visit  
QTc QT interval corrected for heart rate  
Rb retinoblastoma protein  
RBC red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
RP2D  recommended Phase [ADDRESS_797476] operating procedure  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t1/[ADDRESS_797477] upper limit of normal  
US [LOCATION_002]  
Vz/F apparent volume of distribution during the terminal phase  
WHO World Health Organization  
 
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 12 of 103  
G1 Therapeutics CONFIDENTIAL  3. SYNOPSIS  
Title  Phase 1b/2 Safety, Pharmacokinetic, and Efficacy  Study of G1T38 in 
Combination with Osimertinib in Patients with  EGFR 
Mutation -Positive  Metastatic Non -Small Cell Lung Cancer (NSCLC)  
Study Rationale  Non-small cell lung cancers (NSCLCs) represent the vast majority of 
lung cancers around the world, and epi[INVESTIGATOR_3506] 
(EGFR) mutations occur in approximately 15% of NSCLC s in the 
[LOCATION_002] and up to 62%  of NSCLCs in Asia. Osimertinib  
(Tagrisso®) has been established as the second -line standard of care in 
EGFR -positive  NSCLC with a T790M mutation after failure of a 
first-line EGFR tyrosine kinase inhibitor ( TKI), and has also recently 
demonstrated benefit in first-line EGFR -positive NSCLC regardless of 
T790M status . Historical median  progression-free survival ( PFS) with 
second -line osimertinib monotherapy is approximately 10 months, and 
the overall response rate (ORR) is approximately 70%.  Nearly all 
patie nts eventually develop resistance to osimertinib and experience 
disease progression. 
The putative resistance mechanisms to osimertinib include activating 
muta tions in PIK3CA, MEK1, and KRAS; amplifications in MET, 
HER2, and FGFR1;  activation of the IGF1R pathway; and EGFR 
C797S mutation. M any of these are upstream of cyclin -dependent 
kinase 4/6 (CDK4/6), suggesting that  combining G1T38 with 
osimertinib has the potential to block these resistance pathways, delay the time to resistance, pro long PFS, and thus delay the need for 
cytotoxic chemotherapy.  
In a well -established, erlotinib -resistant , T790M -positive NSCLC 
murine model, adding G1T38 to erlotinib treatment resulted in a 
77% delay in tumor growth compared with erlotinib alone; w hereas, 
erlotinib alone  showed no statistically sig nificant change compared 
with vehicle control. Furthermore, the addition of G1T 38 to afatinib 
treatment nearly doubled the  time to resistance when compared  with 
treatment with afatinib  only.  Finally , in murine tumors that became 
resistant to afatinib , the addition o f G1T38 caused stable disease (SD) . 
These results suggest that the addition of G1T38 to an EGFR inhibitor 
could potentially extend PFS in patients with  NSCLC. 
Clinical Phase  1b/2 
Indication  Treatment of  EGFR  T790M mutation -positive  metastatic (Stage IV) 
NSCLC after first -line EGFR TKI failure  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 14 of 103  
G1 Therapeutics CONFIDENTIAL  Study Design  This is a Phase 1b/2, multicenter, open -label study of the safety, 
tolerability, pharmacokinetics (PK), and efficacy  of G1T38 in 
combination with osimertinib for pa tients with EGFR  mutation-positive 
metastatic NSCLC. This open -label study consists of 2 par ts: Part [ADDRESS_797478] of osimertinib on the PK parameters of G1T38 and 
the safety and tolerability (including dose -limiting toxicities [DLTs])  of 
escalating doses of G1T38 in combination with osimertinib to 
determine the recommended Phase 2 dose (RP2D); and Part 2 will be a randomized portion to further evaluate t he safety , tolerability, and 
efficacy  of the RP2D. Both parts of the study include 3 study phases: 
Screening Phase, Treatment Phase, and Survival Follow -up Phase. The 
Treatment Phase begins on the day of the first dose of study drug and 
completes at the Post -Treatment v isit.  
Part 1  
Part 1 Pharmacokinetic  Interaction and Dose-Escalation Cohorts  
Cohort 1:  Six patients will be enrolled in the first cohort in Part [ADDRESS_797479] cancer resistance protein 
(BCRP) transporter protein and osimertinib has been shown to increase 
the area under the concentration -time curve (AUC ) and maximum 
concentration ( C
max) of concurrently administered rosuvastatin, a BCRP 
substrate, by 35% and 72%, respectively.  Patients will receive a single 
oral dose of G1T38 200 mg on Cycle 1 Day -16 and blood samples for 
G1T38 PK evaluation will be collected over  the subsequent 48-hour 
period. Patients will then receive oral osimertinib 80 mg once daily 
without G1T38 on Cycle 1 Days -14 to - 3, and then both G1T38 and 
osim ertinib on Cycle 1 Day -2, after which blood samples for G1T38 
PK evaluation will be collected over the subsequent 48 -hour period. 
Osimertinib once-daily dosing will continue  on Cycle 1 Day -1 and 
through the end of the Treatment Phase . On Cycle 1 Day 1 , patients will 
begin G1T38  once -daily d osing, which will continue through the end of 
the Treatment Phase (note: there is no Day 0 in the study). DLT s will be 
evaluated from Cycle 1 Day -16 through Cycle 1 Day 28 (the DLT 
period) . A safety monitoring committee (SMC) will evaluate all safety 
and available PK data through the DLT period for Cohort 1 prior to the enrollment of additional cohorts.  
Cohorts 2 and beyond:  Following completion of Cohort 1, a dditional 
sequential dose-escalation cohorts may be enrolled using a standard 
3 + [ADDRESS_797480] 
cohort . All d ose escalation/de-escalation recommendations made by [CONTACT_602400], as well as the cumulative safety data 
from all patients enrolled.  
Definition of Dose -Limiting Toxicities  
Dose-limiting toxicitie s are drug -related adverse events (AE s) defined 
as follows:  
• Grade 4 neutropenia  
• ≥ Grade 3 neutropenic infection/febrile neutropenia  
• Grade 4 thrombocytopenia  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 15 of 103  
G1 Therapeutics CONFIDENTIAL  • ≥ Grade 3 thrombocytopenia with bleeding  
• ≥ Grade 3 nonhematologic toxicity (additional criterion for nausea, 
vomiting, diarrhea, or fatigue: lasting > 5 days w ith maximal 
medical management)  
• Liver function test abnormalities meeting Hy’s Law criteria (aspart ate aminotransferase [ AST ] or alanine aminotransferase 
[ALT ] ≥ 3 × upper limit of normal [ULN] and total bilirubin 
≥ 2 × ULN).   All study drugs must be permanently discontinued in 
any patient meeting Hy’s Law criteria.  
Part 2  
In Part 2, eligible patients wil l be enrolled into a randomized portion of 
the study. Patients will be randomized ( 1:1) to receive osimertinib or 
G1T38 (at the RP2D)  + osimertinib , with stratification by [CONTACT_602401] (CNS) metastases (yes versus no) and ethnicity  
(Asian versus non -Asian) . Following screening, patients will begin 
osimertinib or G1T38 + osimertinib onc e-daily oral dosing on Cycle 1 
Day 1 . 
Patients who are initially randomized to receive osimertinib alone may 
crossover to the G1T38 + osimertinib group at the time of disease 
progression as determined by [CONTACT_19375] (BICR). 
An independent data monitoring committee  (IDMC ) shall  review all 
cumulative safety and efficacy data, as well as all available PK data, 
approximately every [ADDRESS_797481] . Patients in Part 2 who are initially randomized to receive 
osimertinib alone may  crossover to the osimertinib + G1T38 arm at the 
time of disease progression .  
Study Duration  Part 1: The duration of Part 1 will be approximately 9 months.  
Part 2: The ORR is expected to read out approxim ately [ADDRESS_797482] 50% of the 
patients in Part [ADDRESS_797483] of  inclusion criteria  are 
provided in Section 7.1.1.   
• Women or men, 18 years or older  
• Histologic or cytologic  confirmed diagnosis of NSCLC  
• Stage IV NSCLC  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 16 of 103  
G1 Therapeutics CONFIDENTIAL  • Documented EGFR mutation ( at any time since the initial diagnosis 
of NSCLC) known to be associated with EGFR TKI sensitivity 
(including G719X, exon 19 deletion, L 858R, L861Q)  
o Part 2 Only:  Tumor T790M mutation-positive status 
based on an appropriate test (tumor biopsy or cell -free 
DNA [cfDNA]) taken after documented disease 
progression on first -line treatment with a first or second  
generation EGFR TKI  
• Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 or 1, with no deterioration over the previous 2 weeks and a 
minimum life expectancy of 12 weeks 
• Evaluable (Part 1 only) or m easurable disease  
• Left ventricular ejection fraction (LVEF) ≥ institution’s lower limit of the reference range  
• Adequate bone marrow reserve and  organ function as demonstrated 
by [CONTACT_132725]:  
o Hemoglobin ≥ 90 g/L  
o ANC ≥ 1.5 × 10
9/L 
o Platelet count ≥ 100 × 109/L 
o Calculated creatinine clearance ≥ 50 mL/minute 
o Total bilirubin ≤ 1.5 × ULN ; < 3 × ULN if the patient has 
documented Gilbe rt’s disease or liver metastases  
o ALT <  2.5 × ULN if no demonstrable liver metastases or 
< 5 × ULN in the presence of liver metastases  
o AST < 2.5 × ULN if no demonstrable liver metastases or 
< 5 × ULN in the presence of liver metastases  
Additional criteria that apply to Part 2 only : 
• Measurable disease as defined in RECIST, Version 1.1, as determined by [CONTACT_602402]  A patient will not be eligible for participation in this study if any of the 
following criteria apply. A full list of exclusion criteria are provided in 
Section 7.1.2.  
o Treatment with any of the following:  
o EGFR TKIs (erlotinib, gefitinib, afatinib , osimertinib) within 
[ADDRESS_797484] dose of study drug; other approved EGFR 
TKIs within [ADDRESS_797485] dose of study drug; antibody based therapy within [ADDRESS_797486] dose of study drug  
o Part 1 only : More than 2 prior line s of cytotoxic chemotherapy 
for advanced NSCLC  
o Part 2 only : Any prior cytotoxic chemotherapy for advanced 
NSCLC  
 Part 2 only : Previous treatment with osimertinib  or other 
T790M active EGFR TKI  
o Blood transfusions or hematopoietic growth factor therapy 
within [ADDRESS_797487] screening visit  
o Prior radiotherapy treatment to > 25% of the bone marrow or 
radiotherapy with a wide field of radiation within 28 days of the 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797488] dose of study drug  
o Patients receiving medications, herbal supplements, or foods  
known to be potent inhibitors of cytochrome P450 ( CYP )3A4 
or orally administered  sensitive substrates of CYP3A4  within  
[ADDRESS_797489] dose of study drug (see Sect ions 8.5.1  and 
8.5.2 ) 
o Patients receiving medications, herbal supplements, or foods  
known to be potent inducers of CYP3A4 within  [ADDRESS_797490] dose of study drug (see Section 8.5.2) 
o Patients receiving medications, herbal supplements, or foods 
known to be potent inhibitors of BCRP within [ADDRESS_797491] dose of study drug (see Section 8.5.2) 
o Part 1  only: Patients receiving medications that raise gastric pH 
within [ADDRESS_797492] dose of study drug (see Section 8.5.5 ). 
 
o Any unresolved toxicities from prior  surgeries or therapy 
> Grade 1 ( Common Terminology Criteria for Adverse Events 
[CTCAE] Version 4.03 ) at the time of starting study drug with 
the exception of alopecia (any grade)  and platinum  therapy -
related peripheral neuropathy (>  Grade 2)  
o Known active uncontrolled or symptomatic central nervous 
system (CNS) metastases, carcinomatous meningitis, or 
leptomeningeal disease as indicated by [CONTACT_4659], cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if 
they are currently asymptomatic and clinically stable off anticonvulsan ts and steroids for at least [ADDRESS_797493] 
dose of G1T38.  
o Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hyp ertension and active bleeding 
diatheses, which in the investigator’s opi[INVESTIGATOR_602388]   
o Known chronic, active infection  
o Cardiac criteria as outli ned in Section  7.1.[ADDRESS_797494] medical history of interstitial lung disease, drug -induced 
interstitial lung disease  (ILD), radiation pneumonitis which 
required steroid treatment, or any evidence of clinically active 
interstitial lung disease  
o Prior hematopoietic stem cell or bone marrow transplantation  
Other Medicinal Products  Osimertinib [ADDRESS_797495] Dosage and 
Administration  G1T38 will be administered orally once daily. The starting dose for Part 1 will be a G1T38 dose of 200 mg  once daily  and subsequent dose 
level s will be determined by [CONTACT_4484] . All patients in Part 2, will 
receive the RP2D selected by [CONTACT_4484]. All doses of G1T38 sh all be 
administered with food.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 19 of 103  
G1 Therapeutics CONFIDENTIAL  2 treatment groups. The odds ratio an d its associated 80 % CI  will be 
presented.   
In addition, potential influences of baseline patient characteristics such 
as age, ECOG performance status, and selected biomarkers on the endpoints may be evaluated to compare the 2 treatment groups.  
For Part 2 of the study, because crossover to G1T38 + osimerti nib is 
allowed for patients following  progress ion on osimertinib alone, the 
treatment effect on OS may be confounded and may not be estimated properly by [CONTACT_602403]. Therefore, an explorat ory 
analysis will be performed using the rank-preserving structu ral failure 
time (RPSFT) method  and Cox model with inverse probability of 
censoring weighting (IPCW)
 to correct for confounding introduced by  
[CONTACT_602404].  
Safety Analysis  
The safety analysis will include  all treated patient s. Descriptive 
statistics of safety will be presented. All treatment -emergent AEs, 
drug-related AEs, serious adverse events ( SAEs ), and drug-related 
SAEs will be tabulated using worst grade per National Cancer Institute 
(NCI ) CTCAE, Vers ion 4.[ADDRESS_797496] 
grade per NCI CTCAE, Version 4.0 3 criteria.  
Rationale for Number of 
Patients It is estimated that up to  36 patien ts will be enrolled in the 
dose-escalation part of the study  (Part 1). The actual number of patients 
will depe nd on the number of dose levels/ cohorts that are tested.   
For the randomized  part of the study (Part 2), it is assumed that the 
overall 1 -sided type I error rate is 0.1 and the type II error rate used to 
compute sample size is 0.20 (corresponding to 80% power). Patients will be randomized using a 1:1 treatment  allocation ratio between the 
2 treatment gro ups ( osimertinib versus G1T38 +  osimertinib).  
Assuming a 10.[ADDRESS_797497] patient is enrolled, the 
calculated total sample size is 98 patients. Allowing for a dropout/ lost-to-follow -up rate of approximately 10% , gives an adjusted 
total sample size of 108  patients for Part 2 . 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 20 of 103  
G1 Therapeutics CONFIDENTIAL  4. INTRODUCTION  
4.1. Background 
The cyclin D/cyclin -dependent kinase 4/6 (CDK4/6)/p16INK4a/retinoblastoma protein (Rb) 
pathway is frequently disrupted in cancer. A majority of human neoplasms maintain 
functional Rb, but have aberrations that increase the activity of CDK4/6, which inhibits Rb 
function and allows cell proliferation (Ortega et al 2002; Shapi[INVESTIGATOR_2152] 2006). As such, CDK4/[ADDRESS_797498] ive small 
molecule inhibitor of the CDK4/6 -cyclin D complex for oral treatment of patients with 
CDK4/6 -dependent tumors, such as non- small cell lung cancer (NSCLC).  
NSCLC represent the vast majority of lung cancers around the world, and epi[INVESTIGATOR_8199] (EGFR ) mutations occur in approximately 15% of NSCLC in the United 
States and up to 62% of cases in Asia. Osimertinib  (Tagrisso
®), a third generation EGFR 
tyrosine kinase inhibitor (TKI ), has been established as the second -line standard of care in 
patients with metastatic  EGFR T790M mutation positive NSCLC whose disease has 
progressed on or after a first -line EGFR TKI , and has also recently demonstrated benefit in 
first- line EGFR -positive NSCLC regardless of T790M status ( Sequist and Neal,  2017; 
Ramalingam et al 2017 ). Standard of care treatment following disease progression with 
osimertinib remains parenteral cytotoxic chemotherapy as no oral treatment options currently 
exist in this setting.  
Historical median  progression- free survival (PFS) with osimertinib monotherapy is 
approximately 10 months, and the overall response rate (ORR)  is approximately 70% 
(Tagrisso Prescribing Information 2017). Nearly all patients eventually develop  resistance to 
osimertinib and experience disease progression.  The putative resistance mechanisms to 
osimertinib include activating mutations in PIK3CA, MEK1, and KRAS, and/or amplifications in MET, human epi[INVESTIGATOR_3506] 2 ( HER2 ), fibroblast growth 
factor receptor 1 ( FGFR1 ), and activation of the insulin- like growth factor 1 receptor 
(IGF1R) pathway; many of these are upstream of CDK4/6 ( Ramal ingam et al 2017; 
Minari  et al 2016; Ko et al 2017).  G1T38 has the potential to block these  resistance 
pathways, delay the time to resistance, and prolong PFS when added to osimertinib, and thus 
has the potential to delay the need for cytotoxic chemotherapy. Nonclinical 
osimertinib -resistant tumor model s are not currently available.  Therefore, the addition of 
G1T38 to either erlotinib  or afatinib, which are first and second generation EGFR inhibitors, 
respectively , has been evaluated in the H1975 mouse model (EGFR
L858R/T790M) to assess 
proof of principle. Tumor growth delay was compared in mice treated with an EGFR 
inhibitor (erlotinib or afatinib) alone or EGFR inhibitor and G1T38. As the EGFRT790M 
mutation is known to accelerate time to resistance to afatinib and erlotinib, it was anticipated 
that erlotinib alone would be ineffective and the time to afatinib resistance would be short. 
As expected, mice treated with erlotinib  showed no statistically significant difference in 
tumor growth when compared to the vehicle only cohort. However, when G1T38 was added to erlotinib treatment, there was a 77 % tumor growth delay when compared to controls, 
suggesting the addition of G1T38 reversed erlotinib resistance. Fu rthermore, the addition of 
G1T38 to afatinib treatment extended time to resistance from  18 days (afatinib alone) to 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 24 of 103  
G1 Therapeutics CONFIDENTIAL  In Study G1T38-01, single or twice daily (total daily dose split into 2 equal doses, taken 
every 12 hours) oral doses of G1T38 in the dose range of 3 to 600 mg/day appeared to be 
well to moderately tolerated in a group of healthy male and female subjects. In most subjects with moderate tolerability, gastrointestinal AEs were the most common moderate intensity treatment- emergent AEs ( TEAEs ). Dosing under fed conditions appeared to improve 
gastrointestinal tolerability. Effects on hematologic parameters were not observed due to the limited du ration of dosing. 
There were no deaths, other serious adverse events ( SAEs ), or AEs that led to withdrawal 
from the study and no subjects experienced severe or life-threatening TEAEs. For subjects treated with G1T38 in Study G1T38-01, 37 (65%) subjects reported a total of [ADDRESS_797499] frequently (≥  20% of subjects) reported 
treatment- related TEAEs by [CONTACT_10607] (MedDRA) system 
organ class (SOC) were gastrointestinal disorders (reported by 60% of pooled G1T38-dosed subjects versus 17% of pooled placebo-dosed subjects) and nervous system disorders (33% 
for both pooled G1T38-dosed subjects and placebo-dosed subjects). The most frequently 
(≥ 10% of all subjects) reported treatment- related TEAEs by [CONTACT_602405] 
(reported by 46% of pooled G1T38-dosed subjects versus 6% of pooled placebo-dosed 
subjects), nausea (33% versus 6%, respectively), headache (18% versus 22%, respectively), 
and fatigue (12% versus 6%, respectively). Note: Six subjects reported ‘loose stool(s)’ that did not meet the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 
definition of diarrhea that requires an increase in stool frequency; however, the MedDRA 
codes ‘loose stool(s)’ to diarrhea. Exclusion of t hese 6 subjects with loose stool(s), resulted 
in 20 out of 57 (35%) of pooled G1T38-dosed subjects reporting diarrhea. The intensity of 
loose stool(s) in all 6  subjects was reported as mild.  
Sixteen (28%) of [ADDRESS_797500] 1 treatment- related TEAE of 
moderate (Grade 2) intensity. The most common treatment- related TEAEs of moderate 
intensity were diarrhea in 6 (11%) subjects, nausea in 5 (9%) subjects, headache in 
5 (9%) subjects, and somnolence in 2 (4%) subjects. In the placebo group, 1 treatment- related headache of moderate severity was reported in 1  (6%) placebo-dosed 
subject. 
Gastrointestinal tolerability of G1T38 was improved by [CONTACT_602406] a high- fat 
meal. Four (50%) of 8 subjects in the fed state versus 8 (1 00%) of [ADDRESS_797501] 1 dose of G1T38 . Dose levels administered included 200  mg once daily 
(n = 6); 100 mg twice daily  (n = 6); 300  mg once daily (n = 3); and 150 mg twice daily  
(n = 3). G1T38 is administered on a continuous daily dosing schedule and the longest 
duration of therapy was [ADDRESS_797502] 2017. One DLT of Grade 4 neutropenia 
has been observed in 1 patient adminis tered 200 mg G1T38 once daily. This patient’s 
neutropenia recovered with dose interruption for [ADDRESS_797503] 
been reported to date. 
Fifteen of 18 patients (83.3%) had at least 1 G1T38- related AE  (Table 4-1) . The most 
common G1T38- related AEs occurring i n ≥ 5 subjects wer e neutrophil count decreased 
(9 subjects [50%]), white cell count decreased (7  subjects [38.9%]), anemia (6 subjects 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 25 of 103  
G1 Therapeutics CONFIDENTIAL  [33.3%]), neutropenia (5 subjects [27.8%]), diarrhea (5 subjects [27.8%]), and nausea 
(5 subjects [27.8%]). 
 
Table 4-1 Summary of G1T38-R elated Adverse Events by [CONTACT_602407] G1T38 -02 (as of [ADDRESS_797504]  2017) 
Preferred Term  G1T38 -02 
 (N = 18)a 
Grade 1 -2 
n (%)  Grade 3  
n (%)  Grade 4  
n (%)  Grade 5  
n (%)  Overall  
n (%)  
Number (%) of patients with any 
G1T38 -related TEAEs 11 (61.1)  3 (16.7)  1 (5.6)  0 15 (83.3)  
Neutrophil count decreased  7 (38.9)  2 (11.1)  0 0 9 (50.0)  
White blood cell count decreased  7 (38.9)  0 0 0 7 (38.9)  
Anaemia  6 (33.3)  0 0 0 6 (33.3)  
Diarrhoea  5 (27.8)  0 0 0 5 (27.8)  
Nausea  5 (27.8)  0 0 0 5 (27.8)  
Neutropenia  3 (16.7)  1 (5.6)  1 (5.6)  0 5 (27.8)  
Haematuria 3 (16.7)  0 0 0 3 (16.7)  
Vomiting  3 (16.7)  0 0 0 3 (16.7)  
Blood creatinine increased  2 (11.1)  0 0 0 2 (11.1)  
Platelet count decreased  2 (11.1)  0 0 0 2 (11.1)  
Alopecia  1 (5.6)  0 0 0 1 (5.6)  
Blood bilirubin increased  1 (5.6)  0 0 0 1 (5.6)  
Blood lactate dehydrogenase increased  1 (5.6)  0 0 0 1 (5.6)  
Blood urea increased  1 (5.6)  0 0 0 1 (5.6)  
Dry eye  1 (5.6)  0 0 0 1 (5.6)  
Dry mouth  1 (5.6)  0 0 0 1 (5.6)  
Lacrimation increased  1 (5.6)  0 0 0 1 (5.6)  
Leukopenia  1 (5.6)  0 0 0 1 (5.6)  
Monocyte count decreased  1 (5.6)  0 0 0 1 (5.6)  
Stomatitis  1 (5.6)  0 0 0 1 (5.6)  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 28 of 103  
G1 Therapeutics CONFIDENTIAL  Based on the DDI information available for osimertinib and the nonclinical evaluation of 
G1T38, it is highly unlikely that G1T38 will alter the PK of osimertinib. This conclusion is based on the mitigating data in Table 4-2. 
Table 4-2 Osimertinib an d G1T38: Potential Risks for Drug -Drug Interactions and 
Mitigating Data  
Potential R isk Mitiga ting D ata 
G1T38 inhibits CYP3A4 (IC 50 = 78 µM) and 
osimertinib is CYP3A4 substrate  The strong CYP3A4 inhibitor itraconazole had no 
clinically meaningful effect on the PK of osimertinib  
 
Osimertinib is a CYP3A4 substrate  G1T38 does not induce CYP3A4  
G1T38 inhibits BCRP (IC 50 = 7.21 µM) and 
osime rtinib is a BCRP substrate  Does not meet F DA thresholda as clinically relevant 
using the following FDA formula: [I]/IC 50 ≥ 0.1, 
where [I] represents the mean anticipated steady -state 
G1T38 total C max for a 600 mg G1T38 dose 
(0.338  µM) 
[I]/IC 50 = 0.338 µM/7.21 µM = 0.0468  
a FDA Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and 
Labeling Recommendations. Feb ruary  2012.  
 
4.4.2. Dose Rationale 
Part 1  
Single doses of up to 600 mg of G1T38 were safely ad ministered in the FIH  study 
 with n o ≥ Grade 3 study G1T38-related AEs observed. The ongoing P hase 1 /2 
patient study  (G1T38-02) utilizing continuous daily doses of G1T38 in combination with 
fulvestrant has examined G1T38 doses of 200 mg once daily, 300 mg once daily, 400 mg 
once daily, 100 mg twice daily, and 150 mg twice daily with no observed SAEs to date and 
only one G1T3 8-related DLT of G rade 4 neutropenia in a patient receiving 200 mg once 
daily, who had a baseline absolute neutrophil count (ANC) of 1500 cells/mL. The neutropenia re covered following a 20-day interruption of G1T38 dosing and re- initiation of 
G1T38 at 150 mg once daily  thereafter . The patient remains on study at this reduced dose for 
> [ADDRESS_797505] 2017, the 400 mg once- daily dose has been determined to be tolerable 
(no DLTs in the 3 patient cohort) by [CONTACT_89804] (SMC)  and the study is 
currently enrolling patients at a G1T38 dose of 500 mg once daily. 
Osimertinib is classified as a weak inhibitor of BCRP according to the FDA Guidance for 
Industry: Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, 
and Labeling Recommendations (2012) . AUC is considered  the mo st relevant parameter in 
terms of G1T38 safety as the chronic administration of CDK4/6 inhibitors such as G1T38 
appears to be the primary factor leading to clinically significant neutropenia, whereas brief relatively higher concentrations (ie, C
max) appear t o have little effect on neutropenia as was 
observed in Study G1T38-01. 
The starting dose of G1T38 will be 200 mg once daily in combination with 80 mg once daily 
osimertinib. This G1T38 dose allows a safety coverage of 100% r elative to the G1T38 dose 
of 400 mg once daily tha t was well  tolerated in the ongoing P hase 1b /2 study (dose escalation 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 29 of 103  
G1 Therapeutics CONFIDENTIAL  ongoing; dose level as of 04 October 2017 was 500 mg once daily). It is anticipated that the 
potential effect of os imertinib on the PK  parameters of G1T38 will not exceed that observed 
with rosuvastatin (a model BCRP substrate). 
Followin g assessment of the safety, tolerability and PK data for the first cohort in this study , 
subsequent cohorts will be enrolled utilizing a 3+3 design as described in Section 6.1.1. 
Part 2  
The doses of G1T38 and osimertinib to be used in Part 2 of the study wi ll be determined 
during Part 1 as described in Section 6.1.1.  4.5. Risk/Benefit Assessment  
The safety profile of G1T38 observed to date in the ongoing P hase 1 /2 study is similar to 
other CDK4/[ADDRESS_797506] common 
drug- related AE and with G rade 1 and 2 gastrointestinal effects (nausea, vomiting, and 
diarrhea) also being observed. There have been no observed G1T38-related pulmonary, 
cardiac, skin, or clinically significant ophthalmic AE s to date (see Section 4.3.1).   
The most common osimertinib- related AEs  (≥ 20%) are diarrhea (41%), rash (34%),  dry skin 
(23%), nail toxicity (22%), and fatigue (22%) ( Tagrisso  Prescribing Information 2017). 
Significantly less frequent, but potentially more severe osimertinib -related AE s include 
pneumonitis/interstitial lung disease, QTc prolongation, cardiomyopathy, and keratitis. Based on extensive nonclinical data and clinical data to date with G1T38, none of these more severe osimertinib -related AEs  have been observed with G1T38 to date. This study includes 
appropriate exclusion criteria, baseline examinations, and on-study monitoring to carefully exclude at-risk patients and to evaluate patients for the development of these more severe osimertinib -related AE s during the course of the study. Management of osimertinib related 
toxicities shall follow the prescribing information for osimertinib (Tagrisso Prescribing 
Information 2017; see Appendix 2). 
Neutropenia, the vast majority Grade 1 or 2, has also been obse rved with osimertinib therapy , 
with up to 2.2% of patients experiencing G rade [ADDRESS_797507] 8 weeks (2 cycles) then every other w eek for the next 
2 cycles. Beginning with Cycle 5 Day 1, patients with stable ≤ Grade [ADDRESS_797508] hematology monitored monthly (Day 1 of each cycle); patients that do not meet this criteria will continue to have every other week assessment of hematologic parameters . The neutropenia induced by [CONTACT_140965]4/6 inhibitors, including G1T38, is reversible 
with interruption of therapy and dose reduction if necessary. Specific guidelines for managing neutropenia are included in Section 8.3.3. 
Patients will be carefully monitored for potentia l gastrointestinal AE s and  managed 
symptomatically with appropriate therapi[INVESTIGATOR_014].  G1T38 will also be dosed with food as this was 
shown t o improve gastrointestinal tolerability in the FIH  study. 
In summary, the potential benefits of extending PFS with osimertinib plus G1T38 and 
delaying the need for cytotoxic chemotherapy outweigh the potential risks of gastrointestinal AEs and neutropenia, both of which are easily monitored and treatable. Furthermore, febrile 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 30 of 103  
G1 Therapeutics CONFIDENTIAL  neutropenia with the CDK4/6 inhibitor palbociclib in combination with fulvestrant has been 
reported in only 0.9% of patients, indicating a low risk to the patient, and neutropenia in general with CDK4/[ADDRESS_797509] majority of patients with treatment interruption and/or dose reduction ( Palbociclib  Prescribing  Information  2017) . 
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 32 of 103  
G1 Therapeutics CONFIDENTIAL  6. INVESTIGATIONAL PLAN  
6.1. Overall Study Design and Plan 
This open- label study consists of 2 parts: Part [ADDRESS_797510] of osimertinib on the 
PK parameters of G1T38 and the safety and tolerability of escalating doses of G1T38 in 
combination with osimertinib to determine the recommended Phase 2 dose (RP2D); and Part 2 will be a randomized portion to further evaluate the safety, tolerability , and efficacy  of 
the RP2D. Both parts of the study include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of t he first dose of 
study drug and completes at the Post -Treatment Visit.  
6.1.1. Part [ADDRESS_797511] of osimertin ib on the PK parameters of G1T38 
and to determine the RP2D of G1T38 in combination with osimertinib by [CONTACT_602408] (including DLTs), tolerability, PK, and efficacy  of escalating doses of G1T38 administered 
with osimertinib.  
During Part 1,  an SMC  will provide oversight and guidance regarding safety concerns, as 
outlined in the SMC Charter.  All dose escalation/de- escalation decisions will made by [CONTACT_181966], which will be comprised of the sponsor, medical monitor, independent medical doctor, and the principal investigator(s). The SMC will make the final dose determination for each subsequent cohort. Therefore the actual dose may differ from the projected dose levels in Table  6-1 as the SMC may determine that intermediate dose levels warrant exploration.  
Part 1 Pharmacokinetic Interaction and Dose -Escalation Cohorts 
Cohort 1: Six patients will be enrolled in the first cohort in Part [ADDRESS_797512] of osimertinib on the PK parameters of G1T38. Projected dose levels are presented in Table  6-1. Patients will receive a single  oral dose of G1T38 200 mg on Cycle 1 Day -16 and 
blood samples for G1T38 PK evaluation will be collected over the subsequent 48-hour period. Patients will then receive oral osimertinib 80 m g once daily without G1T38 on 
Cycle  1 Days -14 to -3, and then both G1T38 and osimertinib on Cycle 1 Day -2, after which 
blood samples for G1T38 PK evaluation will be collected over the subsequent 48-hour period. Osimertinib once-daily dosing will continue on Cycle 1 Day -1 and through the end of the Treatment Phase. On Cycle 1 Day 1, patie nts will begin G1T38 once-daily dosing, 
which will continue through the end of the Treatment Phase (note: there is no Day 0 in the study). DLTs will be evaluated from Cyc le 1 Day -16 through Cycle 1 Day 28 (the DLT 
period). An SMC will evaluate all safety and available PK data through the DLT period for 
Cohort [ADDRESS_797513] 
3 + [ADDRESS_797514] cohort. All dose 
escalation/de-escalation recommendations made by [CONTACT_602409], as well as the cumulative 
safety data from all patients enrolled . Further details with respect to decision making will be 
described in the SMC Charter. If a patient is withdrawn prior to completing all of the 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 33 of 103  
G1 Therapeutics CONFIDENTIAL  assessments during the DLT period for reasons other than toxicity in any cohort in Part 1, the 
patient will be replaced.  
Table  6-1 Projected G1T38 Dose Levels, Part 1 
Cohort  G1T38 Dosea (mg)  
Level 2 dose reduction  100 
Level 1 dose reduction  150 
1 200 
2 300 
3 400 
4 500 
5 650 
a Intermediate dose levels may be explored at the discretion of the SMC 
 
The maximum G1T38 dose in this study  will not exceed 650 mg/day. 
[IP_ADDRESS]. G1T38 Dose Evaluation Criteria 
In the first Cohort of 6 patients, a relatively low dose of G1T38 will be administered to allow 
for a sufficient safety window. This low dose of G1T38 is anticipated to be below the 
maximum tolerated dose (MTD) , even if osimertinib increases the systemic exposure of 
G1T38 (see Section 4.4.2) . However, if ≥  [ADDRESS_797515] been exceeded and a lower G1T38 dose level may be explored. If 1 or fewer patient(s) in the first cohort of 6 experien ce a DLT, then 3 patients may be enrolled at the 
next SMC recommended G1T38 dose level. 
The G1T38 dose evaluation criteria for Cohorts 2 and beyond are listed below.  
• If there is no DLT in a given dose level cohort, then 3 patients may be enrolled at the 
next SMC recommended G1T38 dose level.  
• If there is 1 DLT in a given dose level cohort of 3 patients, an additional 3 patients 
will be enrolled at this G1T38 dose level. If no additional DLTs are observed (ie, 
≤ 1 out of 6 with DLT), escalation may proceed to the next SMC recommended 
G1T38 dose level.  
• If there are ≥ [ADDRESS_797516] been 
exceeded and a lower G1T38 dose level may be explored as determined by [CONTACT_4484] . 
[IP_ADDRESS]. Definition of Dose- Limiting Toxicities (Applicable  to Cycle 1  Day -16 
through Cycle 1 Day 28 in  Part 1)  
Dose -limiting toxicities are drug -related AEs defined as follows:  
• Grade 4 neutropenia 
• ≥ Grade 3 neutropenic infection/febrile neutropenia  
• Grade 4 thrombocytopenia  
• ≥ Grade 3 thrombocytopenia with bleeding 
• ≥ Grade 3 nonhematologic toxicity (additional criteria for nausea, vomiting, diarrhea, 
or fatigue: lasting > 5 days with maximal medical management)  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 34 of 103  
G1 Therapeutics CONFIDENTIAL  • Liver function test abnormalities meeting Hy’s Law criteria ( aspartate 
aminotransferase [ AST ] or a lanine aminotransferase [ ALT ] ≥ 3 × upper limit of 
normal [ ULN] and total bilirubin ≥ 2 × ULN ). All study drugs must be permanently 
discontinued in any patient meeting Hy’s Law criteria. 
Each patient will be evaluated for toxicity during the Treatment Phase. The toxicity of 
G1T38 administered with osimertinib will be assessed by [CONTACT_89791] (NCI) CTCAE , Version 4.03. 
6.1.2. Part 2  
In Part 2, eligible patients will be enrolled into a randomized portion of the study. Patients will be randomized ( 1:1) to receive osimertinib or G1T38 (at the RP2D) + osimertinib . 
Following screening, patients will begin  once daily oral dosing with osimertinib or 
G1T38 + osimertinib on Cycle 1 Day 1.  
Patients who are initially randomized to receive osimertinib alone may  crossover  to 
G1T38 + osimertinib at the time  of disease progression as determined by [CONTACT_193400]  (BICR) . Patients should continue osimertinib monotherapy 
uninterrupted prior to crossover. The date of crossover is defined as the first date the patient 
receives G1T38 + osimertinib.  
An independent data monitoring committee ( IDMC) sha ll review all cumulative safety  and 
efficacy  data , as well as all available PK data, approximately every [ADDRESS_797517] to decision making will be described in the IDMC Charter.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 35 of 103  
G1 Therapeutics CONFIDENTIAL  7. STUDY POPULATION  
7.1. Selection of Patient s 
Overall, up to 144 patients may  be enrolled in the study.  
In Part 1, up to 36 pati ents may be enrolled.  
In Part 2, up to 108 patients will be enrolled. 
7.1.1. Inclusion Criteria  
Patient eligibility sh all be reviewed and documented by [CONTACT_602410]’s study team before patients are included in the study. Patients must meet all 
of the following inclusion criteria to be e ligible for enrollment into the study: 
1. Provision of signed and dated written informed consent prior to any study specific procedures, sampling, and analysis 
2. Women or men, 18 years or older 
3. Histologic or cytologic confirmed diagnosis of NSCLC 
4. Stage IV NSCLC  
5. Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q). Patients in Part [ADDRESS_797518] result that has been FDA -approved and performed 
in a Clinical Laboratory Improvement Amendments (CLIA)- certified laboratory (US 
sites) or based on a locally available EGFR mutation test result that has been performed in an accredited laboratory (sites outside of the US).  
a. Part 2 Only : Tumor EGFR T790M mutation-positive status after documented 
disease progression on first -line treatment with a  first or second generation 
EGFR  TKI . Patients will be enrolled based on a locally available T790M 
mutation test result (tumor biopsy or cell -free DNA [cfDNA] ) that has been 
FDA-approved (eg, cobas
® EGFR Mutation Test v2, FoundationOne CDx™) 
and performed in a CLIA- certified laboratory (US sites) or a locally available 
T790M mutation test result (tumor biopsy or cf DNA) that has been performed 
in an accredited laboratory (sites outside of the US). Testing for the presence of the T790M mutation in plasma specimens (cfDNA) is recommended only 
in patients for whom a tumor biopsy cannot be obtained. 
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no 
deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 36 of 103  
G1 Therapeutics CONFIDENTIAL  7. Evaluable dis ease (Part 1 only) or m easurable disease as defined in Response Evaluation 
Criteria in Solid Tumors (RECIST ), Version 1.1, as determined by [CONTACT_941] i nvestigator  
• Measurable disease is defined as having at least 1  lesion, not previously 
irradiated, that can be accurately measured at baseline as ≥ [ADDRESS_797519] diameter (except lymph nodes, which must have short axis ≥ 15 mm) 
with computerized tomography (CT) or magnetic resonance imaging (MRI), 
which is suit able for accurate repeated measurements.  
8. Left ventricular ejection fraction (LVEF) ≥ institution’s lower limit of the reference range  
9. Adequate bone marrow reserve or organ function as demonstrated by [CONTACT_132725]: 
a. Hemoglobin ≥ 90 g/L  
b. ANC ≥ 1.5 × 10
9/L 
c. Platelet count ≥ 100 × 109/L 
d. Calculat ed creatinine clearance ≥ 50 mL/min (by [CONTACT_3158]- Gault formula 
[Cockcroft and Gault 1976] or 51Cr-EDTA)   
e. Total bilirubin ≤ 1.5 × ULN; < 3 × ULN if the patient has documente d 
Gilbert’s disease or liver metastases  
f. ALT < 2.5 × ULN if no demonstrable liver metastases or < 5 × ULN in the presence of liver metastases  
g. AST < 2.5 × ULN if no demonstrable liver metastases or < 5 × ULN in the presence of liver metastases  
10. Contraception: Patients must be willing to comply with the requirements for contraception as described in Section 8.10 
Additional criteria that apply to Part 2 only : 
11. Measurable disease as defined in RECIST, Version 1.1 , as determined by [CONTACT_093] 
7.1.2. Exclusion Criteria  
A patient will not be eligible for participation in this study if any  of the following criteria 
apply. 
1. Treatment with any of the following: 
a.  EGFR TKIs (erlotinib, gefitinib, afatinib, osimertinib) within [ADDRESS_797520] dose of study drug; other approved EGFR TKIs within [ADDRESS_797521] dose of study drug 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797522] dose of study drug; antibody based therapy within [ADDRESS_797523] 
dose of study drug 
c. Part 1: More than 2 prior lines of cytotoxic chemotherapy for advanced NSCLC  
d. Part 2:  Previous treatment with osimertinib or other T790M active  EGFR TKI  
e. Part 2:Any prior cytotoxic chemotherapy for advanced NSCLC 
2. Major surgery within [ADDRESS_797524] screening visit  
4. Prior radiotherapy treatment to >  25% of the bone marrow or radiotherapy with a wide 
field of radiation  within [ADDRESS_797525] dose of study drug, including but not limited to the following : 
a. Inhibitors , for example: clarithromycin, diltiazem, erythromycin, grapefruit 
juice, itraconazole, ketoconazole, nefazodone, ritonavir, telithromycin, and verapamil  
b. Substrates , for example: astemizole, cisapride, cyclosporine, 
dihydroergotamine, ergotamine, everolimus, pi[INVESTIGATOR_3924], quinidine, sirolimus, and tacrolimus 
6. Patients receiving  medications, herbal supplements, or foods known to be potent induc ers 
of CYP3A4  within [ADDRESS_797526] dose of study drug, including but not limited 
to the following: 
a. Inducers, for example: carbamazepi[INVESTIGATOR_050], Hypericum perforatum  (St. John’s 
wort), phenobarbital, phenytoin, rifampin 
7. Patients receiving medications,  herbal supplements, or foods known to be potent 
inhibitors of BCRP within [ADDRESS_797527] dose of study drug, including but not limited to the following:  
a. Inhibitors , for example: sulfasalazine, curcumin, turmeric supplements, 
cyclosporine, eltrombopag 
8. Part 1:  Patients receiving medications that raise gastric pH within [ADDRESS_797528] 
dose of study drug such as proton pump inhibitors (eg, omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, dexlansoprazole), H2 blockers (eg , nizatidine, 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 38 of 103  
G1 Therapeutics CONFIDENTIAL  famotidine, cimetidine, ranitidine), and antacids (eg, sodium bicarbonate, calcium 
carbonate, aluminum-based antacids, magnesium compounds, alginic acid).  
9. Any unresolved toxicities from prior surgeries o r therapy of > Grade 1 (CTCAE , 
Version  4.03) at the time of starting study drug with the exception of alopecia (any grade) 
and platinum therapy- related peripheral neuropathy (> Grade 2)  
10. Known active uncontrolled or symptomatic central nervous system (CNS) metastases, 
carcinomatous meningitis, or leptomeningeal disease as indicated by [CONTACT_4659], cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they are currently asymptomatic and clinically stable off 
anticonvulsants and steroids for at least [ADDRESS_797529] dose of G1T38. 
11. Any evidence of severe or unc ontrolled systemic diseases, including uncontrolled 
hypertension and active bleeding diatheses, which in the investigator’s opi[INVESTIGATOR_602389] e 
compliance with the protocol 
12. Known chronic, active infection including but not limited to hepatitis B virus, hepatitis C virus, tuberculosis, and human immunodeficiency virus (HIV); screening for chronic 
conditions is not required 
13. Any of the following cardiac criteria: 
a. Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms ( ECGs ), using the screening clinic ECG machine 
derived QTc value 
b. Any clinically important abnormalities in rhythm, conduction, or morphology or resting ECG, eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250  msec 
c. Any factors that increase the risk of QTc prolongation (see Appendix [ADDRESS_797530] 
of drugs) or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under [ADDRESS_797531] degree relatives, or any concomitant medication known to prolong the QT interval 
d. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class III or IV as defined by [CONTACT_89792] [NYHA] functional classification system)  
e. Known history of stroke, cerebrovascular accident, or myocardial infarction within [ADDRESS_797532] medical history of interstitial lung disease  (ILD) , drug-induced ILD, radiation 
pneumonitis which required steroid treatment, or any e vidence of clinically active 
interstitial lung disease  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797533], or previous significant bowel resection  that would preclude adequate absorption of study drug 
16. History of other malignancies, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated a) in situ carcinoma of the uterine cervix, b) prost ate cancer, or c) superficial bladder cancer; or (3) other curatively 
treated solid tumor with no evidence of disease for ≥  3 years 
17. History of hypersensitivity to active or inactive excipi[INVESTIGATOR_602390] a similar chemical structure or cla ss to study drug 
18. Women who are pregnant or breastfeeding 
19. Psychiatric illness/social situations that would limit study compliance  
20. Legal incapacity or limited legal capacity  
21. Judgement by [CONTACT_602411] i f the 
patient is unlikely to comply with study procedures, restrictions, and requirements 
22. Prior hematopoietic stem cell or bone marrow transplantation  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 40 of 103  
G1 Therapeutics CONFIDENTIAL  8. TREATMENTS  
8.1. Treatments Administered  
Study drugs will be administered as fol lows  for each cohort in Part 1 of the study: 
• Cycle 1 Day  -16: single oral dose of G1T38  
• Cycle 1 Day -15: no study drug administered 
• Cycle 1 Days -14 to - 3: oral once -daily doses of osimertinib  
• Cycle 1 Day -2: single oral dose of osimertinib and G1T38 
• Cycle 1 Day -1: single oral dose of osimertinib  
Beginning with Cycle 1 Day 1, oral once-daily doses of G1T38 and osimertinib will 
commence ( Figure 8-1 ). 
Figure 8-1 Study Schema: Part 1  
 
 
PTV  = Post-Treatment v isit 
There is no Day 0 in the study. A treatment cycle is defined as 28 days.  
In Part 2, eligible patients will be randomized (1:1) to receive o simertinib or G1T38 (at the 
RP2D)  + osimertinib . Randomized patients will begin once-daily oral dosing of osimertinib 
or G1T38 + osimertinib  on Cycle 1 Day 1 ( Figure 8-2). 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 41 of 103  
G1 Therapeutics CONFIDENTIAL  Figure 8-2 Study Schema: Part 2  
 
PTV = Post -Treatment v isit 
 
8.1.1. Investigational Medicinal Product  (IMP)  
G1T38 will be initially supplied initially as oral capsules containing 25 or  100 mg 
equivalents of G1T38 free base. Excipi[INVESTIGATOR_602391], hypromellose, mannitol, croscarmellose sodium, and magnesium stearate.  
Once available, G1T38 supply will be transitioned to oral tablets containing 50 or 200 mg of 
G1T38 free base.  Excipi[INVESTIGATOR_602392], hypromellose, croscarmellose sodium,  and magnesium stearate. The film coating 
contains polyethylene glycol:  polyvinyl alcohol graft copolymer, talc, titanium dioxide, mono-and di- glycerides, and partially hydrolyzed polyvinyl alcohol.  
Alternate  strengths may be utilized in the event that they become available.    
Packaging and Labeling   
G1T38 is  packaged in high-density polyethylene (HDPE) bottles and sealed with 
child -resistant closures. Bottles of G1T38 capsules contain 30 capsules; whereas, bottles of 
G1T38 tablets contain [ADDRESS_797534]/designee who will inventory the contents and document them 
according to the drug accountability requirements (Section 8.1.4).  
Storage  
The G1T38 shall be stored at 15°C to 30°C.  
Study drugs will be stored in a locked cabinet/secure area under applicable storage conditions 
at the site and only the pharmacist/designee and designated personnel will have access to the study drugs. 

G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 42 of 103  
G1 Therapeutics CONFIDENTIAL  8.1.2. Other  Investigational Medicinal Products  
[IP_ADDRESS]. Osimertinib  
A description of the formulation, packaging and labeling for osimertinib  can be found in the 
respective current prescribing information (see  Appendix 2).   
Store osimertinib bottles at 25 °C (77°F). Excursions are permitted to 15 °C to 30°C (59 °F to 
86°F).  
8.1.3. Procedure for Dispensing  
Dispensing instructions will be provided in the Pharmacy Manual and will be maintained in 
the pharmacy records.   
8.1.4. Investigational Product Accountability  
The pharmacist/designee will verify the  integrity of the clinical study  supplies (storage 
conditions, correct amount received, condition of shipment, bottle numbers, etc.) according to the investigative site’s standard operating procedures ( SOPs) . Additional requirements 
may be found in the Pharmacy Manual. 
8.2. Method of Assigning Patients to Treatment Groups 
A unique patient identification number and allocation to a cohort/treatment group will be 
assigned by [CONTACT_190331] -response system  (IWRS ).  
8.3. Dose, Dosing Regimen, and Route 
8.3.1. G1T3 8  
The starting dose of G1T38 is 200 mg  orally (see Section 4.4.2) . Dose escalation / 
de-escalation  is described in Section [IP_ADDRESS]. The maximum G1T38 dose level  explored sha ll 
not exceed  650 mg per day.  
In Part 1, all patients will receive single doses of G1T38 on Cycle 1 Day -16 and Cycle 1 Day -2 and begin continuous G1T38 once-daily dosing on Cycle 1 Day 1 (note: there is no Day 0 in the study). In Part 2, patients randomized to osimertinib with G1T38 will begin G1T38 once-daily continuous oral dosing on Cycle 1 Day 1. 
G1T38 should be taken with food. G1T38 should be taken at approximately the same time 
each day .  
8.3.2. Osimertinib     
All patients will receive continuous oral osimertinib 80 mg once daily (starting on Cycle 1 Day -14 in Part 1 and on Cycl e 1 Day 1 in Part 2). 
Osimertinib may be taken with or without food, and should be taken at approximately the same time each day.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 43 of 103  
G1 Therapeutics CONFIDENTIAL  8.3.3. Dose Modification 
[IP_ADDRESS]. G1T3 [ADDRESS_797535] 
be discussed with the medical monitor.   
Dose Modifications for G1T38-R elated Hematologic Toxicity  
The G1T38 dose level adjustments in Table 8-1 are based on hematologic adverse reactions, 
except lymphopenia (unless associated with clinical events, eg, opportunistic infections). 
Table 8-1 G1T38 Dose  Level  Adjustments  Based  on G1T38 -related Hematologic  
Toxicities  
CTCAE Grade of 
Hematologic Toxicity   
G1T38 Dose Adjustment  
Grade 3  Continue G1T38 and repeat CBC at next scheduled visit . 
≥ Grade 3 neutropenia  
associated with a documented 
infection or fever ≥ 38.5 °C  Withhold G1T38 and monitor counts weekly until ANC > 1 x 109/L. 
Resume therapy at the next lower dose.  
≥ Grade 3 thrombocytopenia 
associated with bleeding  Withhold G1T38 and monitor counts weekly until platelet count ≥ 75 x 109/L.  
Resume therapy at the next lower dose.  
Grade 4  Withhold G1T38  and monitor counts weekly  until ANC > 1 x 109/L and 
platelet count > 75 x 109/L.  
Resume therapy at the next lower dose.  
ANC = absolute neutrophil count; CBC = complete blood count; CTCAE = Common Terminology Criteria for Adverse 
Events 
 
Granulocyte-colony stimulating factor  
The optimal treatment for G1T38-induced neutropenia is to withhold G1T38. 
Granulocyte-colony stimulating factor (G- CSF) will not work in this setting because G1T38 
induces a G1 cell cycle arrest in myeloid precursors that cannot be overcome by G- CSF. 
Withholding G1T38 treatment will allow neutrophil counts to recover naturally as the study drug concentrations in the body decline and the myeloid precursors are released from 
G1 arrest  and mature to produce neutrophils. If the patient experiences neutropenia lasting 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797536] the medical monitor to discuss the 
use of G- CSF. 
In the event that the patient experiences a drug -related hematologic toxicity warranting dose 
reduction, which may be related to G1T38 or osimertinib (ie , the investig ator is unable to 
determine whether the toxicity is related to G1T38 or osimertinib), the investigator shall 
dose- reduce G1T38 first . If the toxicity does not resolve following the first dose reduction of 
G1T38, then the investigator shall use clinical judgement to determine if a second G1T38 dose reduction is warranted or if osimertinib dose reduction is warranted. In this situation, discussion with the medical monitor is recommended. 
Dose Modifications for G1T38-R elated Nonhematologic Toxicity 
For any ≥ Grade 3 G1T38- related nonhematologic toxicity  (excluding alopecia) persisting 
despi[INVESTIGATOR_4570] , withhold treatment with G1T38 until symptoms resolve to 
Grade ≤  2 (if not considered a safety risk for the patient). T reatment  should be resumed  at the 
next lower dose level of G1T38.  
Any patient with liver function test abnormalities meeting Hy’s Law criteria (AST or ALT 
≥ 3 × ULN and total bilirubin ≥ 2 × ULN ) must have all study drugs permanently 
discontinued. 
Patients with gastrointestinal AEs (eg, nausea, vomiting, diarrhea) may have the total daily 
dose split, as close to 50:50 as possible, to a morning dose and an evening dose as a means to potentially improved gastrointestinal tolerability. Dose -splitting is not permitted during the 
DLT  evaluation period or the PK evaluation period. In this situation, discussion with the 
medical monitor is suggested.  
[IP_ADDRESS]. Osimertinib  
Dose modifications for osimertinib for adverse reactions are to be made a ccording to 
Table 8-2. 
 
If a patient  experiences a Grade 3  (CTCAE)  or higher and/or unacceptable toxicity (any 
grade), where the i nvestigator considers the AE of concern to be specifically associated wit h 
osimertinib  (and not attributable to the disease or disease- related processes for which the 
patient is being treated), dosing will be interrupted and supportive therapy administered as 
required in accordance with local practice/guidelines.  
If a toxicity resolves or reverts to ≤  Grade 2  (CTCAE)  within 3 weeks of onset, treatment 
with osimertinib may be restarted at the same dose or a lower dose using the rules below for dose modifications ( Table  8-2)  and with dis cussion and agreement with the sponsor’s study 
team p hysician as needed. There will be no individual modifications to dosing schedule in 
response to toxicity, only potential dose reduction or dose interruption.  
 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 45 of 103  
G1 Therapeutics CONFIDENTIAL  If the toxicity does not resolve to ≤  Grade 2  (CTCAE)  after 3 weeks, then osimertinib 
therapy shall be permanently discontinued and the patient shall be observed until resolution 
or stabilization of the toxicity. 
Patients experiencing an y of the following AE s will not be permitted to restart osimertinib 
treatment: 
• Corneal ulceration 
• Interstitial lung d isease (ILD)  
• QTc interval prolongation with signs/symptoms of serious arrhythmia 
• Symptomatic congestive heart failure or asymptomatic left ventricular dysfunction 
that persists ≥ 4 weeks  
• Liver function test abnormalities meeting Hy’s Law criteria ( AST or ALT ≥ 3 × ULN 
and total bilirubin ≥ 2 × ULN ). All study drugs must be permanently discontinued in 
any patient meeting Hy’s Law criteria.    
Table  8-2 Recommended Dose Modifications for Osimertinib -Related  Adverse 
Reactions 
Target Organ  Adverse Reactiona Dose Modification  
Pulmonary  Interstitial lung disease/ pneumonitis  Permanently discontinue osimertinib  
Cardiac  QTc in terval > [ADDRESS_797537] 
2 separate ECGs  Withhold osimertinib u ntil QTc interval is 
< 481 msec or recovery t o baseline , then resume 
at 40 mg dose  
QTc interval prolongation with 
signs/symptoms of life -threatening 
arrhythmia  Permanently discontinue osimertinib  
Symptomatic congestive heart failure 
or asymptomatic left ventricular 
dysfunction that persists ≥ 4 weeks  Permanently discontinue osimertinib  
Other  ≥ Grade 3 adverse reaction  Withhold osimertinib for up to 3  weeks  
If improvement to Grade 0 to 2 within 
3 weeks  Resume at 80 or 40 mg daily  (investigator’s 
discretion)  
If no improvement within 3 weeks  Permanently discontinue osimertinib  
ECG = electrocardiogram; QTc = QT interval corrected for heart rate   
a Adverse reactions graded by [CONTACT_572091],  
Version  4.03 .  
Source: Table copi[INVESTIGATOR_602393] 1 of the osimertinib package insert (see Appendix  2) 
 
In the event that the pati ent experiences a drug -related hematologic toxicity, which may be 
related to G1T38 or osimertinib, the investigator shall dose-reduce G1T38 first (refer to 
Section [IP_ADDRESS]). 
In the event that the patient receiving G1T38 + osimertinib experien ces an 
osimertinib -related toxicity requiring permanent discontinuation of osimertinib, the patient 
may continue G1T38 monotherapy at the discretion of the investigator. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 46 of 103  
G1 Therapeutics CONFIDENTIAL  Details regarding the mana gement of specific AE s related to osimertinib are discussed in 
Sections [IP_ADDRESS].1 to  [IP_ADDRESS].6. 
[IP_ADDRESS].1. Interstitial Lung Disease/Pneumonitis -like Toxicity  
If new or worsening pulmonary symptoms (eg, dyspnea) or radiological abnormality 
suggest ive of ILD  is observed, an interruption in osimertinib  dosing is recommended, and the 
sponsor study team shall be informed. It is strongly recommended to perform a full diagnostic workup (including high- resolution computed tomography [HRCT] , blood and 
sputum culture, hematological parameters)  to exclude alternative causes such as 
lymphangitic carcinomatosis, infection, allergy, cardiogenic edema , or pulmonary 
hemorrhage. In the presence of confirmatory HRCT scans where other causes of respi[INVESTIGATOR_591254], a diagnosis of ILD  shall  be considered and osimertinib  
treatment permanently discontinued.  
In the absence of a diagnosis o f ILD,  osimertinib  may be restarted f ollowing consultation 
with the s ponsor’s study team physician.  
[IP_ADDRESS].2. QTc Prolongation 
Patients with QTcF prolongation to > [ADDRESS_797538] study treatment interrupted and 
regular ECGs performed until resolution to <  481 msec , and then restarted at a reduced dose 
of osimertinib 40 mg. If the toxicity does not resolve to < 481 msec  within 21 days, the 
patient will be permanently withdrawn from osimertinib treatment.  
[IP_ADDRESS].3. Keratitis  
Keratitis was reported in 0.7% (n  = 6) of the 833 patients treated with osimertinib in the 
AURA studies. Patients presenting with signs and symptoms suggestive of keratitis such as 
acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, 
and/or red eye shall  be referred promptly to an ophthalmology specialist.  
[IP_ADDRESS].4. Changes in Cardiac Contractility  
Across cli nical trials, LVEF  decreases of ≥ 10% and a drop to <  50% occurred in 4.0% 
(26/655) of patients treated with osimertinib w ho had baseline and at least 1  follow- up LVEF 
assessment. Based on the available clinical trial data, a causal relationship between effects on changes in cardiac contractility and osimertinib has not been established. In patients with 
symptomatic congestive heart failure or asymptomatic left ventricular dysfunction that 
persists ≥ 4 weeks, perman ently discontinue osimertinib therapy ( Table  8-2).  
Permanent Discontinuation Due to T oxicity  
Patients experiencing corneal ulceration, ILD , symptomatic congestive heart failure or 
asymptom atic left ventricular dysfunction that persists ≥ 4 weeks, or QTc prolongation with 
signs/symptoms of serious arrhythmia  will not be permitted to restart osimertinib treatment.  
Any patient with liver function test abnormalities meeting Hy’s Law criteria (AST or ALT 
≥ 3 × ULN and total bilirubin ≥ 2 × ULN ) must have all study drugs permanently 
discontinued. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 47 of 103  
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS].5. Skin Reactions 
Changes in the CTCAE grade of skin reactions will be collected in the AE e CRF.  
Photographs of skin reactions may be collected and these photographs shall  be avail able for 
central review by [CONTACT_602412], if patient consent is obtained.  
Skin biopsies may be taken of skin reactions.  
[IP_ADDRESS].6. Diarrhea  
In the event that th e patient experiences drug -related diarrhea, which may be related to 
G1T38 or osimertinib, the investigator shall dose-reduc e G1T38 first (refer to 
Section  [IP_ADDRESS]).  
Changes in CTCAE grade of diarrhea will be captured in the AE eCRF.  
8.4. Randomization and Blinding  
Parts 1 and 2 are  open label . In Part 1, no treatment randomization will be required. In Part  2, 
patients will be randomized ( 1:1) to receive  osimertinib or G1T38 ( at the RP2D ) + 
osimertinib . Study drug administration shall begin no more than 96 hours after 
randomization. Randomization wil l be stratified according to 2  factors: the presence or 
absence of CNS  metastases at screening and Asian versus non -Asian ethnicity . 
8.5. Prior and Concomitant Medications and Procedures 
All concomitant medications including prescription medications, over- the-counter 
preparations, herbal remedies, traditional remedies, growth factors, blood products, and 
parenteral nutrition taken during the [ADDRESS_797539] recent World Health 
Organization (WHO) Drug Dictionary version. 
If medically feasible, patients taking regular medication(s) , with the exception of prohibited 
medications (see below), should be maintained on those medications throughout the study 
period.  Refer to Appendix 4 for additional details regarding concomitant medications. 
8.5.1. CYP3A4 S ubstrates  
G1T38 has the potential to inhibit CYP3A4/5 in both a competitive and time-dependent 
manner based on in vitro studies. Using the FDA recommended model-based predictions in 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 48 of 103  
G1 Therapeutics CONFIDENTIAL  the guidance for drug interaction studies ( US Department of Health and Human Services, 
Food and Drug Administration, Center for Drug Evaluation and Research, 2012), G1T38 
has the potential to significantly inhibit CYP3A4 in the gut and thus may have a clinically significant effect on orally administered CYP3A4 substrates with a narrow therapeutic index and such drugs are prohibited during participation in this study (beginning [ADDRESS_797540] dose of study drug).   
• Prohibited, orally administered CYP3A substrates with a narrow therapeutic 
index , including but not limited to  the following : 
o Astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, 
everolimus, pi[INVESTIGATOR_3924], quinidine, sirolimus, and tacrolimus  
• Caution  should be used with concurrent use of other orally administered CYP3A 
substrate drugs with consideration of dose reduction of the substrate if clinical signs and symptoms of toxi city emerge (eg, muscle aches with 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors).  
 
The model-based calculation for inhibition of CYP3A4 in the liver predicts a marginal inhibitory effect by G1T38 and therefore the likelihood of a clinically s ignificant drug 
interaction for CYP3A substrates administered via routes other than oral (eg, intravenous, transdermal, inhalation, etc.) is low.  
• Caution  should be used with concurrent use of non- orally administered CYP3A 
substrates with a narrow therapeu tic index with consideration of dose reduction of the 
substrate if clinical signs and symptoms of toxicity emerge (eg, increased somnolence with transdermal fentanyl or intravenous  midazolam).  
8.5.2. CYP3A4 Inhibitors and Inducers  
G1T38 is a substrate for CYP3A4, although the extent of metabolism by [CONTACT_097]3A4 is expected to be low in humans since the in vitro clearance of G1T38 in human liver microsomes and hepatocytes was low. G1T38 exposure may be altered by [CONTACT_602413], herbal supplements, or foods th at are strong CYP3A inhibitors or inducers and such 
drugs are prohibited during participation in this study (beginning [ADDRESS_797541] dose of study drug).  
• Prohibited, strong inhibitors of CYP3A4 , including but not limited to  the 
following: clarithromycin, itraconazole, ketoconazole, nefazodone, erythromycin, grapefruit juice, telithromycin, diltiazem, verapamil, and ritonavir  
  
• Prohibited, strong or moderate CYP3A inducers, including but not limited to the 
following: phenytoin, rifampin, carbamazepi[INVESTIGATOR_050], St John’s Wort, phenobarbital, 
bosentan, modafinil, and nafcillin  
In addition, c oadministration of osimertinib with a strong CYP3A4 inducer decreased the 
exposure of osimertinib compared to administration of osimertinib alone. Decreased osimertinib exposure may lead to reduced efficacy ( Tagrisso  Prescribing Information  2017).  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797542] try to avoid concomitant use of medications, herbal 
supplements, and/or ingestion of foods that are known to be potent inducers of CYP3A4 
whenever feasible, but patients may receive any medication that is clinically indicated for 
treatment of AE s. Such drugs must have been discontinued for an appropriate period before a 
patient  enter s screening and for a period of [ADDRESS_797543] of osimertinib on the PK of G1T38 
via the mechanism of B CRP inhibition by [CONTACT_602414]. Therefore, patients are prohibited 
from taking drugs, herbal supplements, or foods that are strong BCRP inhibitors during 
participation in this study (beginning [ADDRESS_797544] dose of study drug). 
 
• Prohibited, strong inhibitor s of BCRP , including but not limited to the following: 
sulfasalazine, curcumin, turmeric supplements, cyclosporine, eltrombopag 
 
8.5.4. BCRP substrates  
Patients taking concomitant medications whose disposition is dependent upon BCRP and 
which have a narrow therapeutic index should be closely monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication while  receiving 
osimertinib. Guidance on medications to avoid, medications that require close monitoring, and on washout periods is provided in the appendices. 
Patients taking rosuvastatin should have creatine phosphokinase levels monitored (due to 
BCRP -mediated increase in exposure). If the patient experiences any potentially relevant 
AEs suggestive of muscle toxicity including unexplained muscle pain, tenderness, or 
weakness, particularly if accompanied by [CONTACT_21936], rosuvastatin must be stopped and 
any appropriate further management should be taken. 
8.5.5. Gastric pH Elevating Agents  
The solubility of G1T38 is pH dependent. Drugs that raise gastric pH may alter the 
bioavailability of G1T38 and confound the interpretation of PK data. During Part [ADDRESS_797545] dose of study drug until after the final  PK sample is collected on Cycle 1 Day 1 . Such 
medications include proton pump inhibitors (eg, omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole, dexlansoprazole), H2 blockers (eg, nizatidine, famotidine, cimetidine, ranitidine), and antacids (eg, sodium bicarbonate, calcium carbonate, aluminum- based antacids, magnesium compounds, alginic acid).  
 
8.5.6. CYP2C8 Inhibitors and Inducers  
G1T38 is a substrate for CYP2C8, although the extent of metabolism by [CONTACT_097]2C8 is 
expected to be low in humans since the in vitro clearance of G1T38 in human liver 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 50 of 103  
G1 Therapeutics CONFIDENTIAL  micro somes and hepatocytes was low. G1T38 exposure may be altered by [CONTACT_602413], herbal supplements, or foods that are strong CYP2C8 inhibitors or inducers. 
• Caution  should be exercised with concomitant use of drugs that are strong inhibitors 
of CYP2C8 (eg, gemfibrozil, quercetin, sulfinpyrazone, trimethoprim, and 
nicardipi[INVESTIGATOR_050]).  
• Caution  should be exercised with concomitant use of drugs that are strong or 
moderate inducers of CYP2C8 (eg, rifampin, phenobarbital, and carbamazepi[INVESTIGATOR_050]). 
8.6. Systemic Corticosteroid Use 
Steroids given for physiological replacement (up to 10 mg per day of prednisone or 
equivalent) , as anti -emetics, or by [CONTACT_12699], ophthalmic, or topi[INVESTIGATOR_602394]. Short 
courses (up to 21 days) of  steroids are allowed  to treat acute conditions if  medically 
necessary .   
8.7. Supportive Care for Gastrointestinal Adverse Events 
Medications to treat gastrointestinal AEs are allowed at any time during the study, as 
indicated (eg, loperamide for diarrhea, 5-HT3 antagonists for nausea/vomiting, etc.). Such medications shall not be used as primary prophylaxis prior the onset of any ga strointestinal 
AEs. After a patient has experienced a gastrointestinal AE, supportive treatments may be used as secondary prophylaxis if the patient continues to experience the AE.  
8.8. Additional Cautions  
G1T38 inhibited P-gp, BCRP, MATE1, MATE2- K, and OCT1 a nd 2 membrane transporters 
and therefore caution should be exercised with concomitant use of drugs that are substrates 
for these transporters (Section 4.2.2 ; Appendix 4).  MATE2 -K is involved with tubular 
secretion of creatinine and inhibition of MATE2-K by G1T38 may cause an increase in 
serum creatinine levels unrelated to true changes in renal function. 
G1T38 is a substrate and inhibitor of P -gp and BCRP efflux transporters. G1T38 exposure 
may be altered by [CONTACT_602415] P-gp or 
BCRP.  Caution should be exercised with concomitant use of drugs that are strong inhibi tors 
or inducers of P-gp. Use of strong inhibitors of BCRP during participation in this study is prohibited. 
The use of herbal medicine or traditional remedies is not recommended during the active 
treatment phase.  
8.9. Concomitant Radiotherapy or Surgery 
Pallia tive radiotherapy is not allowed within the DLT period. In  Part 1  (after the DLT period) 
and in Part 2, palliative radiotherapy may be permitted to control symptoms (eg, treatment of 
painful bony lesions or brain or thoracic lesions) provided that the lesi ons were known to be 
present at the time of study entry and the investigator clearly documents that the need for palliative radiotherapy is not indicative of disease progression. Refer to Appendix 6 for additional guidelines on radiotherapy. 
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797546] a negative serum beta human chorio nic 
gonadotropin (β -hCG) test result at screening  and not be breast feeding prior to start of 
dosing.  
Females must be either postmenopausal, surgically sterile, or agree to use 2 forms of highly 
effective contraception from the start of the study until 4 months after  discontinuation of 
study drug. 
Highly effective methods of contraception are those that result in a low failure rate (ie, less 
than 1% per year) when used consistently and correctly. These include the following: 
• Established use of oral, injected, or implanted hormonal methods of contraception 
(stable dose at least 3  months prior to dosing)  
• Placement of an intrauterine device or intrauterine system  
• Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with  spermicidal foam/gel/film/cream/suppository. Barrier 
methods alone (without spermicide) are not acceptable methods. Likewise, 
spermicide alone is not an acceptable method.  
• Male sterilization (with the appropriate post vasectomy documentation of the absence 
of sperm in the ejaculate). For female patients on the study, the vasectomized male 
partner should be the sole partner for that patient.  
True abstinence, when this is in line with the preferred and usual lifestyle of the patient. 
Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. 
Postmenopausal is defined as meeting 1, 2, or 3 below: 
1. At least [ADDRESS_797547] serum levels of estradiol and follicle stimulating hormone within the laboratory’s reference range for postmenopausal females 
Acceptable surgical sterilization techniques are complete or partial hysterectomy or bilateral 
tubal ligation with surgery at least [ADDRESS_797548] 2 months prior to dosing.  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797549] s of G1T38 and osimertinib  receipt, 
dispensing, including the applicable lot numbers, bottle numbers, and pi[INVESTIGATOR_602395].  
G1 Therapeutics, Inc.  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 02 September 2019   Page 53 of 103  
G1 Therapeutics CONFIDENTIAL  9. STUDY SCHEDULE  
The procedures and assessments to be performed during the study are outlined in Table  9-1 
(Part 1) and Table  9-2 (Part 2). 
G1 Therapeutics  
Clinical Study Proto col G1T38- 03  G1T38 
 
Version: 4.0, dated [ADDRESS_797550]-
Treat-
ment 
Visit 
(+10) Day -16 Day -14 
(+ 1) Day -2 
(± 1) Day 1 
(+ 2) Day 8 
(± 2) Day 15 
(± 2) Day 22 
(± 2) Day 1 
(± 3) Day 15 (±  3) 
[as required  
in Cycle 5 
and beyond]  
Informed consent  X            9.1 
EGFR mutation 
status  X            
Medical/surgical 
history  X            
Archival tumor 
sample (if 
available)  X            10.3 
Demographics and 
baseline 
characteristics  X            10.6.3  
Vital signs  X X  X X  X  X  X X 10.6.3  
Inclusion/  exclusion 
criteria  X            7.1 
Physical 
examination, 
including weight  X           X 10.6.4  
Symptom -directed 
physical 
examination   X   X  X  X X X  
Height  X            10.6.3  
Full ophthalmic 
exam ination  X Perform if the patient experiences any visual symptoms  10.6.6  
ECOG performance 
status  X X   X    X  X X 7.1.1  
Blood  sample for 
cell-free DNA   X   X 
(Cycle 
2 only)   X 
(Cycle 
1 only)  
  X  
(odd 
Cycles 
only)    X 10.2 
G1 Therapeutics  
Clinical Study Proto col G1T38- 03  G1T38 
 
Version: 4.0, dated [ADDRESS_797551]-
Treat-
ment 
Visit 
(+10) Day -16 Day -14 
(+ 1) Day -2 
(± 1) Day 1 
(+ 2) Day 8 
(± 2) Day 15 
(± 2) Day 22 
(± 2) Day 1 
(± 3) Day 15 (±  3) 
[as required  
in Cycle 5 
and beyond]  
Pregnancy test  X X          X Table 10-5 
and 10.6.2 ; 
(includes 
Cycle 5 and 
beyond 
decrease in  
monitoring 
frequency ) Clinical chemistry  X X   X  X  X X X X 
Hematology  X X   X X X X X X X X 
Urinalysis  X X   X    X  X X 
Cystatin C   X Only if serum creatinine > ULN  
ECG  
X X  X X 
(Cycle 
2 only)     X  
X X 10.6.5  
Echocardiogram/ 
MUGA scan X    
  
  C3D1 and every third 
cycle  (12 weeks ± 7 
days) thereafter    10.6.7 
Tumor assessments 
(RECIST v1.1)  X    After every even cycle  (± 7 days) relative to C1 D1; after 
[ADDRESS_797552] cycle  (± 7 days) relative to C1D1  X  
10.1 CT/MRI brain  X    After every even cycle  (± 7 days) relative to C1D1 if indicated; 
after [ADDRESS_797553] cycle  (± 7 days) relative to C1D1 X  
Optional tumor 
biopsy at time of 
progression            X  10.4 
Enrollment   X           9.1 
Dispense study 
drug  X   X    X    8.1.3  
Dose with G1T38 
(Part  1 only)  X  X Daily dosing with G1T38 beginning on Cycle 1 Day 1    
8.1 Dose with 
osimertinib  
(Part 1  only)   Daily dosing with osimertinib beginning on Cycle 1 Day -14   
Plasma samples for 
PK analysis  (Part 1)   X  X         10.5.1  
G1 Therapeutics  
Clinical Study Proto col G1T38- 03  G1T38 
 
Version: 4.0, dated [ADDRESS_797554]-
Treat-
ment 
Visit 
(+10) Day -16 Day -14 
(+ 1) Day -2 
(± 1) Day 1 
(+ 2) Day 8 
(± 2) Day 15 
(± 2) Day 22 
(± 2) Day 1 
(± 3) Day 15 (±  3) 
[as required  
in Cycle 5 
and beyond]  
Concomitant 
medications and 
procedures   At every visit  8.5 
Adverse events   At every visit  10.6.1  
C = Cycle; CT = computed tomography; D = Day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; MRI = magnetic resonance imaging; MUGA  = multigated 
acquisition; PK  = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors ; ULN = upper limit of normal  
G1 Therapeutics  
Clinical Study Proto col G1T38- 03  G1T38 
 
Version: 4.0, dated [ADDRESS_797555]-Treatment Visit 
(+10) Day 1 
(± 2) Day 8 
(± 2) Day 15 
(± 2) Day 22 
(± 2) Day 1 
(± 3) Day 15 (±  3)  
[as required 
in Cycle 5 
and beyond]  
Informed consent  X         9.[ADDRESS_797556] be 
T790M positive  X         
Medical/surgical 
history  X         
Archival tumor 
sample (if available)  X         10.3 
Demographics and 
baseline 
characteristics  X         10.6.3  
Vital signs  X X  X  X  X X 10.6.3  
Inclusion/exclusion 
criteria  X         7.1 
Physical examination, 
including weight  X        X 10.6.4  
Symptom -directed 
physical examination   X  X  X X X  
Height  X         10.6.3  
Full ophthalmic 
exam ination  X Perform if the patient experiences any visual symptoms  10.6.6  
ECOG performance 
status  X X    X  X X 7.1.1   
Blood  sample for 
cell-free DNA   X   X (Cycle 
1 only)   X (odd 
Cycles 
only)    X 10.2 
G1 Therapeutics  
Clinical Study Proto col G1T38- 03  G1T38 
 
Version: 4.0, dated [ADDRESS_797557]-Treatment Visit 
(+10) Day 1 
(± 2) Day 8 
(± 2) Day 15 
(± 2) Day 22 
(± 2) Day 1 
(± 3) Day 15 (±  3)  
[as required 
in Cycle 5 
and beyond]  
Pregnancy test  X X 
(C1 only)        X Table 10-5 and 
10.6.2  
(includes Cycle 5 
and beyond 
decrease in 
monitoring 
frequency) Clinical chemistry  X X  X  X X X X 
Hematology  X X X X X X X X X 
Urinalysis  X X    X  X X 
Cystatin C   X Only if serum creatinine > ULN  
Electrocardiogram  X X    X  X X 10.6.5  
Echocardiogram/ 
MUGA scan X 
  
  C3D1 and every third cycle   
(12 weeks ± 7 days) 
thereafter  X  10.6.7  
Tumor assessments 
(RECIST v1.1)  X After every even cycle  (± 7 days) relative to C1D1; aft er [ADDRESS_797558] cycle  (± 7 days) relative to C1D1  X  
10.1 CT/MRI brain  X After every even cycle  (± 7 days) relative to C1D1 if indicated; after [ADDRESS_797559] cycle  (± 7 days) relative to C1D 1 X  
Optional tumor biopsy 
at time of progression        X  10.4 
Randomization   X        8.4 
Dispense study drug   X    X    8.1.3  
Dose osimertinib  ± 
G1T38  Daily dosing with osimertinib ± G1T38   8.19.2  
Blood samples for 
G1T38 PK   X (C2 
only)  X (C1 
only) X (C1 
only)     10.5.1  
Concomitant 
medications and 
procedures   At every visit  8.5 
Adverse events   At every visit  10.6.1  
C = Cycle; CT = computed tomography; D = Day; ECOG = Eastern Cooperative Oncology Group; MRI = magnetic resonance imaging; MUGA  = multigated acquisition; 
PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; ULN = upper limit of normal  
 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797560] dose of study drug is 
administered  (ie, 21 days prior to Cycle 1 Day -16 in Part 1 or  21 days prior to Cycle 1 Day  1 
in Part 2). Written informed consent must be obtained from each patient before the initiation of any screening procedures. After a patient has given informed consent, eligibility will b e 
determined by a review of the inclusion/exclusion criteria  (see Section 7.1 ) and completion 
of all screening procedur es outlined in Table  9-1 (Part 1) and Table  9-2 (Part 2).  
Patients that are EGFR TKI treatment na ive in Part [ADDRESS_797561] result that has been FDA -approved and performed in a 
CLIA- certified laboratory (US sites) or based on a locally available EGFR mutation test 
result that has been performed in an accredited laboratory (sites outside of the US).  
For Part 2, tumor EGFR T790M mutation- positive status after documented disease 
progression on first -line treatment with a first or second generation EG FR TKI  is required.  
Patients in Part [ADDRESS_797562] result (tumor biopsy or cfDNA) that has been FDA -approved (eg, cobas
® EGFR Mutation Test v2  
and FoundationOne CDx™) and performed in a CLIA- certified laboratory (US sites) or a 
locally available T790M mutation test result (tumor biopsy or cfDNA) that has been performed in an accredited laboratory (sites outside of the US). Testing for the presence of the T790M mutation in plasma specimens ( cfDNA) is rec ommended only in patients for 
whom a tumor biopsy cannot be obtained. 
Available , most recent  archival tumor tissue (eg, block or slides) will be collected and 
banked for assessment of relevant DNA, RNA, and protein markers, such as those involved 
in the CDK4/[ADDRESS_797563] (see Section 10.3). For additional guidance, please refer to the 
Laboratory  Manual.  
Concomitant medications will be monitored continuously from the time of informed consent through the Post -Treatment Visit. Ad verse events are captured after  the first dose of study 
drug. Medical events that occur prior to first dose  of study drug (G1T38 and/or osimertinib) 
shall  be captured on the Medical History page of the electronic case report form ( eCRF ).   
Eligibility will be determined prior to enrollment (Part 1) or randomization (Part 2) and the start of st udy drug dosing. Eligible patients will be instructed on all protocol requirements, 
including any restrictions on concomitant medication usage (see Section 8.5 ). 
9.2. Treatment Phase 
Adverse events an d concomitant medications will be monitored throughout the study.  
Study drugs will be administered as described in Section  8.1. 
 The timing for assessments and procedures to be performed during the treatment period is  
outlined  in Table  9-1 (Part 1) and Table  9-2 (Part 2). 
Patients that crossover from the osimertinib group to the G1T38 + os imertinib group  
following confirmation of radiographic disease progression by [CONTACT_602416] 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 60 of 103  
G1 Therapeutics CONFIDENTIAL  for assessments and procedures as outlined in  Table  9-2 beginning with Cycle 1 Day 1, 
including tumor assessments, until disease progression on G1T38 + osimertinib.  
9.3. Post-Treatment  Visit /Early Termination 
Patients will return to the study center for a Post -Treatment  visit [ADDRESS_797564] dose 
(+ 10 days) . The procedures and assessments to be performed at this visit are outlined in 
Table  9-1 (Part 1) and  Table  9-2 (Part 2). 
After  completing the Post -Treatment visit, patients will enter the long -term Survival 
Follow-up Phase. 
9.4. Survival Follow- up Phase  
Follow-up shall  be attempted and documented for each patient that is in the long -term 
Survival Follow-up Phase at least once every [ADDRESS_797565]  50% of the patients 
enrolled to Part [ADDRESS_797566] died. This will be considered the end of study.  However, patients who are still receiving treatment at this time  shall continue to receive study treatment 
until the crit eria for study drug discontinuation are met. 
 The following information will be collected  for all patients : 
 
• Survival status  
• Details of any anticancer treatment  
 For patients who have not had disease progression at the time of study drug discontinuation, tumor assessments should be performed every 8 weeks until the occurrence of progressive disease or study completion.   
9.5. Unscheduled Visits  
Additional visits can be performed at the discretion of the i nvestigator.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797567] version 1.1 will be the 
primary outcome measure used to determine progression-free survival (PFS) and best overall response (BOR) in Part 2 of this study. All imaging assessments includin g unscheduled visit 
scans shall  be collected on an ongoing basis and sent to a sponsor -appointed imaging vendor. 
The methods used at baseline for assessment of tumo r burden [CT or MRI scans of chest and 
abdomen (including liver and adrenal glands)] must be used at each subsequent follow-up assessment. Any other areas of disease involvement sh all be additionally investigated based 
on the signs and symptoms of individual patient s. The baseline assessment sh all be 
performed within [ADDRESS_797568] dose of 
study drug. Subsequent assessments are to be performed after every even cycle (every 8 weeks relative to Cycle 1 Day  1) until objective disease progressi on. After [ADDRESS_797569] cycle  (every 12 
weeks ± 1  week)  relative to Cycle 1 Day 1. If a patient has a radiological response (CR or 
PR), a confirmatory radiological assessment shall be performed at least [ADDRESS_797570] noted.  It is important to follow the assessment schedule as closely as possible. If scans are performed outside of the scheduled visit (± 1 week) and the patient has not progressed, every attempt shall  be made to perform the subsequent scans at their 
scheduled time points. Any other sites at which new disease is suspected shall  also be 
appropriately imaged. In Part 2, patients that c rossover from the osi mertinib group  to the 
G1T38 + osimertinib group  following BICR confirmation of radiographic disease 
progression shall  continue tumor assessments after every even cycle ( every 8 weeks relative 
to the crossover date) until objective disease progression. After [ADDRESS_797571] cycle  (12 
weeks ± 1 week) until disease progression .  
Patients with known or suspected brain metastases at screening shall have a CT/MRI of the 
brain prior to starting study drug. These patient s shall be followed up on study with repeated 
CT/MRI assessment, using the same frequency as RECIST assessments. The same modality 
for CT/MRI sh all be used for a patient throughout the study. Brain met astases will be 
assessed as non target lesions  (NTLs) .  
If the investigator is in doubt as to whether progression has occurred, particularly with response to NTLs  or the appearance of a new lesion, it is advisable to continue treatment 
until the next scheduled assessment or sooner if clinically indicated and reassess the patient’s status. If repeat scans confirm progression, then the date of the initial scan shall  be declared 
as the date of progression.  
For those patients who have not progressed at the time of study drug discontinuation, tumor assessments should  continue every 8 weeks from the previous, regularly scheduled scan until 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797572]-treatment scans and has not had a scan within the prior 4 weeks, perform tumor assessment at the Discontinuation visit.  
The same method of assessment (CT or MRI) shall  be used to characterize tumors at 
screening and at all follow -up assessments. If positron emission tomography ( PET) is used, it 
shall  also be accompanied by [CONTACT_15209][INVESTIGATOR_89768].  
RECIST Version 1.[ADDRESS_797573] version 1.1. All 
radiological scans for all subjects (including those at unscheduled visits, or outside visit windows) will be provided to the BICR. Prior radiotherapy reports for subjects (at baseline) 
and information on biopsied lesions will also be provided to the BICR as appropriate.  
Further de tails of the BICR  will be documented in the Blinded Independent Re view Charter.  
10.1.1. Tumor Lesions: Identification and Follow -up 
[IP_ADDRESS]. Measurable Lesions  
Measurable tumor lesions are defined as tumor lesions with a longest diameter (measured in 
at least 1 dimension) with a minimum size as follows ( Eisenhauer 2009):  
• [ADDRESS_797574] or MRI (with a scan slice thickness of no greater than 5 mm) 
Measurable lymph nodes must be ≥ [ADDRESS_797575] or MRI (with a scan slice thickness of no greater than 5 mm); only the short axis is to be measured at baseline and follow-up. 
Lytic bone lesions or mixed lytic- blastic lesions with a soft tissue component meeting the 
definition of measurability above can be considered measurable lesions. Cystic lesions 
representing cystic metastases that meet the definition  of measurability described above can 
be considered measurable lesions. If present, noncystic lesions should be selected as target lesions for this study. 
A tumor lesion that has been previously irradiated may be considered measurable if 
unequivocal growth of the lesion has been demonstrated.  
Target lesions:  At baseline, up to 5 measurable tumor lesions/lymph nodes (with a 
maximum of 2  lesions per organ) should be identified as target lesions that will be followed 
to quantitate the status of disease during the study. Lesions with the longest diameter, that are 
representative of all involved organs, and for which reproducible repeated measurements can 
be obtained should be selected as the target lesions.  
At baseline and each follow -up time point (see Table  9-1), each target lesion should be 
measured and the overall tumor burden will be calculated as the sum of the diameters of the 
target lesions (longest diameter [LD] for tumor lesions and short axis for lymph nodes) and documented in the eCRF. If a target lesion fragments into multiple smaller lesions, the LDs of all fragmented portions are added to the sum of the diameters. If multiple lesions coalesce, the LD of the coalesced lesion will be included in the sum of the diameters. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 63 of 103  
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS]. Nonmeasurable Lesions  
Nonmeasurable lesions include tumor lesions with a longest diameter < 10 mm, lymph nodes 
with ≥ 10 to < [ADDRESS_797576] disease, lymphangitic involvement of skin or lung, or abdominal masses/abdominal organomegaly identified by [CONTACT_602417] ( Eisenhauer 2009).  
Nontarget lesions:  All other lesions (or sites of disease) identified at base line should be 
identified as NTLs and recorded in the eCRF. Measurements of these lesions are not required, but the presence, absence, or unequivocal progression of each NTL  should be 
recorded in the eCRF at each follow -up time point. Multiple NTLs  in the same organ may be 
noted as a single item on the eCRF.  
[IP_ADDRESS]. New Lesions 
Any new lesions should be identified and recorded at each follow-up assessment, as these are 
markers of disease progression. As defined in the RECIST, Version 1.1 guidelines (Eisenhauer 2009), new lesions include the following: 
• A lesion in an anatomical location that was not scanned at baseli ne 
• Equivocal new lesion of small size that with continued therapy and follow-up is 
found to progress and represent new disease (progression should be considered as of 
the date of the initial scan) 
• Negative positron emission tomography with 2-deoxy-2- [fluor ine-18]fluoro-D-
glucose (FDG- PET) at baseline, but has a positive FDG -PET at follow -up 
• No FDG-PET at baseline and a positive FDG- PET at follow -up that corresponds to a 
new site of disease as confirmed by [CONTACT_4654] (date of disease progression should be the date o f the initial abnormal FDG -PET scan)  
Note: Findings attributable to differences in scanning technique or a change in type of imaging (CT versus MRI) and findings representing something other than tumor (eg, healing or flare of existing bone lesions, necrosis of a liver lesion) should not be considered new lesions.  
10.1.2. Definitions of Tumor Response and Disease Progression  
The determinat ion of tumor response and progression will be based on the 
RECIST,  Version  1.1 criteria ( Eisenhau er 2009). The definitions for tumor response per the 
RECIST, Version 1.1 criteria are as follows:  
[IP_ADDRESS]. Evaluation of Target Lesion Response 
• Complete response (CR) : Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm. 
• Partial response (PR) : At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum of diameters.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 64 of 103  
G1 Therapeutics CONFIDENTIAL  • Progressive disease (PD) : At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. 
• Stable disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on study. 
A response category of not evaluable (NE) is to be used when there is inadequate information 
to otherwise categorize the response status.   If a patient has a radiological response (CR or 
PR), a confirmatory radiological assessment shall be performed at least [ADDRESS_797577] noted.  
[IP_ADDRESS].  Evaluation of Nontarget Lesions 
• Complete response (CR) : Disappearance of all NTLs  and normalization of tumor 
marker level. All lymph nodes must be < 10 mm short axis. 
• Non-CR/Non -PD: Persistence of 1 or more NTLs  and/or m aintenance of tumor 
marker level above the normal limits.  
• Progressive Disease (PD) : Unequivocal progression of existing NTLs  or the 
appearance of at least 1 new lesion.  
• To achieve “unequivocal progression” on the basis of nontarget disease, there must be an overall substantial worsening in nontarget disease, such that, even in the presence of SD or PR in target lesions , the overall tumo r burden has increased 
sufficiently to merit discontinuation of therapy. A modest “increase” in size of [ADDRESS_797578] noted.  
[IP_ADDRESS]. Evaluation of Overall Response at Each Time Point  
Patients who have at least 1 postdose tumor assessment (CT scan or MRI) will be considered 
evaluable for tumor response.  
Categoriz ation of objective tumor response assessment at each visit will be based o n 
RECIST  Version 1.1: CR, PR, S D and PD. Target lesion progression will be calculated  in 
comparison to when the tumor burden was at a minimum (ie, smallest sum of diameters 
previously recorded on study). In the absence of progression, target lesion tumo r response 
(CR, PR, SD) will be ca lculated in comparison to the baseline tumor measurements obtained 
before starting treatment.  
Table 10-1 describes the evaluation of overall response at each time point based on target and NTL  responses at each time point, as well as the appearance of new lesions. Evaluation of 
overall response at each t ime point for patients with NTLs  only may be found in Appendix 5. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797579] response recorded from randomization  until disease progression. 
Confirmation of CR and PR is required as described in Sections [IP_ADDRESS] and [IP_ADDRESS].  
Table 10-1 Evaluation of Overall Response at Each Time Point for Patients with 
Target Lesions 
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD/not evaluated  No PR 
SD Non-PD/not evaluated  No SD 
NE Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response, PR= partial response, SD = stable disease, PD = progressive disease, NE = not evaluable  
Source: ( Eisenhauer 2009) 
 
10.2. Cell-Free DNA  
Blood samples for cfDNA analysis will be drawn  at th e time points outlined in Table  9-1 and 
Table  9-2. Beginning with Cycle 3 Day 1, cfDNA samples shall be collected on Day 1 of odd 
numbered Cycles (ie, Cycles 3, 5, 7, etc.). After [ADDRESS_797580] blood samples collected for cfDNA at the crossover date. 
The samples will be used for analysis  related to the effects of G1T38 on the tumor, including 
correlation with clinical efficacy endpoints. The processed samples may be stored up to 
15 years; handling and storage are to be found in the Laboratory Manual. 
10.3. Archival Tumor Tissue 
If available , archival tumor tissue (eg, block or slides) will be collected and banked for 
assessment of relevant DNA, RNA, and protein markers, such as those involved in the 
CDK4/[ADDRESS_797581]. For additional guidance, please refer to the Laboratory Manual. 
10.4. Optional Tumor Biopsy at Time of Disease Progression  
Optional fresh tumor biopsies at the time of disease progression may be collected and banked 
for analysis of relevant DNA, RNA, and protein markers, such as those involved in resistance 
pathways. For additional guidance, please refer to the Laboratory Manual. 
 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 66 of 103  
G1 Therapeutics CONFIDENTIAL  10.5. Pharmacokinetic Assessments  
10.5.1. Pharmacokinetic Sampling  
Blood samples for measurement of G1T38 and osimertinib concentrations will be collected 
as described below and outlined in Table  9-1 (Part 1) and Table  9-2 (Part 2). Information on 
blood sample collection, handling and storage can be found in the Laboratory Manual.  
Part [ADDRESS_797582] be administered by [CONTACT_602418] 1 Day -16 and 
Cycle  1 Day  -2.  
Pharmacokinetic blood samples for the measurement of osimertinib trough concentration and 
the G1T38 pre- dose concentration in plasma will be collected from all patients in Part 1 on 
Cycle 1 Day  -2. Th ese sample s should be taken prior to  (within 60 minutes) the morning 
dose of osimertinib and G1T38.  The doses of G1T38 and osimertinib should be taken together, but G1T38 may be given up to 60 minutes after the osimertinib dose. 
The actual times of blood sample collections should be documented in the eCRF.  
Table  10-2 Part 1: Cycle 1 Day - 16 and C ycle 1 Day - 2 Blood Sampling Scheme  
 Time Point (h) R elative to G1T38 dose  on Cycle 1 Day -16 and on Cycle 1 Day -2 
Sample  
 0 
(Pre-
dose)  1 
 2 
 3 
 4 
 6 
 8 
 24 
 
 32 48  
 
Window  -60 
minutes  (± 10 minutes)  (± 20 minutes)  (± 3 hoursa) 
h = hour  
Actual times  will be recorded in the eCRF.  
a Samples must be a minimum of 5 hours apart . 
 
Part 2  
Patients Randomized to G1T38 + Osimertinib 
Sparse blood sampling for population PK analysis of G1T38 will be collected during Part 2 
for patients randomized to G1T38 + osimertinib. The goal of this sparse sampling is to obtain G1T38 steady -state blood samples from participating  patient s at the following time 
points/intervals  relative to G1T38 dosing: predose and at [ADDRESS_797583] a total of 4 blood samples taken, 1 during each time point/interval (see Table  10-2). 
On Cycle [ADDRESS_797584] the patient via telephone prior to the Cycle 1 Day 15 visit to remind the patient not to take the morning dose of G1T38.   
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 67 of 103  
G1 Therapeutics CONFIDENTIAL  On Cycle 1 Day 22, a blood sample shall be obtained 3 to 6 hours postdose. On Cycle 2 
Day 1, a blood sample shall be obtained 6 to 8 hours postdose. It is anticipated that patients 
will self -administer G1T38 at a range of times during the day and that clinic visits may occur 
at any  time throughout the day during normal business hours. The investigator is encouraged 
to work with the patient to schedule visits at an appropriate time of day in order to obtain the blood samples during the specified time intervals. 
Table 10-3 Part 2 Bl ood Sampling Scheme for G1T38 Population PK Analysis  
Sample  1 2 3 4 
Cycle/Day  Cycle 1 Day 15 Cycle 1 Day 22 Cycle 2 Day 1  
Time point  Predose  1-3 hours postdose  3-6 hours postdose  6-8 hours postdose  
Notes  G1T38 administered in clinic    
 
 
10.5.2. Pharmacokinetic  Parameters  
Pharmacokinetic parameters to be derived  for G1T38  are listed in 
Table  10-4. Pharmacokinetic parameters will not be estimated for osimertinib .  
Additionally, for Part 2, a population PK model will be developed to estimate the PK  
parameters of G1T38   

G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797585] 3 points on the terminal 
phase of the log- linear plasma concentration -time curve.  
t1/[ADDRESS_797586] quantifiable concentration 
using the linear -up log -down trapezoidal rule.  
AUC inf Area under the concentration -time curve from time zero extrapolated to infinity using the linear -
up log -down trapezoidal rule.  
CL/F  Clearance after oral administration, calculated as:  
CL/F = Dose/AUC 0-∞ (G1T38 only)  
Vz/F  Volume of distribution in the terminal elimination phase, calculated as:  
Vz/F = (CL/F)/ λz (G1T38 only)  
 
M/P Ratio  Metabolite to parent ratio calculated as G1T30 AUCinf /G1T38 AUCinf  
 
10.6. Safety Assessments  
Safety evaluations w ill begin  after the first dose of any study drug and continue throughout 
the study. Safety evaluations will include monitoring of AEs, vital signs measurements, 
physical examinations, ECGs, echocardiograms/  multigated acquisition ( MUGA) scan s, 
ophthalmic exams, and clinical laboratory assessments. 
Toxicity will be graded by [CONTACT_602419], Version 4.03. 
10.6.1. Adverse Events and Serious Adverse Events  
Adverse events are captured following the first dose of study drug. All AEs should be reported within [ADDRESS_797587] returned to baseline, or it is deemed that further recovery is unlikely. 

G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 69 of 103  
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS]. Definition of Adverse Event 
An AE  is defined as any untoward medical occurrence in a patient administered a medicinal 
product that does not necessarily have a causal rel ationshi p with this treatment. An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the s tudy (investigational) product.  
Adverse events include the following: 
• All suspected study drug- related adverse events  
• All reactions from medication overdose, abuse, withdrawal, sensitivity, or toxicity  
• Apparently unrelated illnesses, including the worsening of a pre- existing illness (see 
pre-existing c onditions below) 
• Injur y or accidents ( Note that if a medical condition is known to have caused the 
injury or accident [eg, a fall secondary to dizziness], the medical condition [dizziness] and the accident [fall] should be reported as 2 separate AEs). The outcome of the 
accident (eg , hip fracture secondary to the fall) should be recorded under c omments.  
• Abnormalities in physiological testing or physical examination (findings that require 
clinical interventio n or further investigation beyond ordering a repeat [confirmatory] 
test) 
• Laboratory abnormalities that are clinically significant and require clinical 
intervention or further investigation (beyond ordering a repeat [confirmatory] test) unless they are asso ciated with an al ready reported clinical event. Laboratory 
abnormalities associated with a clinical event (eg, elevated liver enzymes in a patient with jaundice) should be described under comments on the report of the clinical event rather than listed as a separate AE.  
An AE does not include: 
• Medical or surgica l procedures (eg, surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure may be an AE 
• Pre-existing diseases or conditions present or detected at the start of the study that do 
not worsen 
• Situations where an untoward medical  occurrence has not occurred (eg , 
hospi[INVESTIGATOR_63805], social, and/or convenience admissions) 
• Overdose of either study drug or concomitant medication without any signs or 
sympto ms 
• Progression of the malignancy under study, including signs and symptoms progression  
• Disease progression can be considered as a worsening of a patient ’s condition 
attributable to the disease for which the investigational product is being studied. It 
may be an increase in the severity of the disease under study and/or increases in 
the symptoms of the disease. The development of new, or progression of existing 
metastasis to the primary cancer under study should be considered as disease progression and not an AE  
• Hospi[INVESTIGATOR_54596] 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797588] information. The sponsor or designee shall be responsible for 
determinin g expectedness; this is not the responsibility of the investigator. 
• An Adverse Drug Reaction (ADR)  is defined as an AE that is caused by a drug (aka 
drug- related AE). An unexpected ADR  is an adverse reaction, the nature or severity 
of which is not consistent with the applicable product information ( eg, IB for an 
unapproved inves tigational medicinal product). All noxious and unintended responses 
to a medicinal product related to any dose should be considered ADRs. The phrase “responses to a medicinal product” means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility,  ie, the rel ationship 
cannot be ruled out. All serious and unexpected ADRs will have expedited reporting 
to the regulatory agencies following the ICH requirements 
It is the responsibility of the investigator to document all AEs that occur during the study and 
every effort should be made to adequately capture all  possible AEs. Pa tients should be 
encouraged to report AEs spontaneously or in response to general, nondirected questioning. Adverse events should be reported on the appropriate page of the eCRF. 
[IP_ADDRESS]. Definition of Serious Adverse Event 
The International Council for Harmonisation ( ICH) topic E2A on Clinical Safety Data 
Management, Definitions and Standards for Expedited Reporting defines an SAE  as any 
untoward medical occurrence that at any dose:  
• Resu lts in death  
• Is life threatening  
NOTE: The term "life threatening" in the definition of "serious" refers to an event in 
which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.  
• Requires inpatient hospi[INVESTIGATOR_1081] 
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect 
Medical and scientific judgment should be exercised in deciding whether expedited reporting (see Section  [IP_ADDRESS])  is appropriate in other situations, such as important medical events that 
may not be immediately life threatening or result in death or hospi[INVESTIGATOR_30506]. These should also usually be considered serious. Examples of such events are intensive treatment in an emergency room or at home for all ergic bronchospasm; 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse. 
To ensure there is no confusion or misunderstanding of the difference between the terms 
“serious” and “severe”, the following note of clarification is provided: 
The term “severe” is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 71 of 103  
G1 Therapeutics CONFIDENTIAL  relatively minor medical sig nificance (su ch as severe headache). This is not the same as 
“serious,” which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a patient’s life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations. 
Hy’s Law  
Prompt reporting (via the SAE expedited reporting system) of cases meeting Hy’s law 
criteria (AST or ALT ≥  3 × ULN and total bilirubin ≥  2 × ULN) is required for compliance 
with regulatory guidelines. The investigator is responsible for, without delay, determining whether a patient meets potential Hy’s law criteria.  Any patient with liver function test 
abnormalities meeting Hy’s Law criteria must have all study drugs permanently discontinued. 
Additional Reporting Requirements for O simertinib  
The following will also be reported to pharmacovigilance : any osimertinib overdose; if a 
patient taking osimertinib begins lactating ; or if a male patient taking osimertinib fathers a 
child during the treatme nt period, including the Post- Treatment Follow -up visit.  If these 
events also meet the criteria to be considered an SAE, they shall be reported as such.  
Handling of Deaths 
 
All deaths that occur during the study, or within the follow-up period after the administration  
of the last dose of investigational product, should be reported as described below. 
Death, which is unequivocally due to disease progression, should be communicated to the 
study monitor at the next monitoring visit and should be documented in the e CRF module,  
but should not be reported as a SAE during the study 
Where death is not clearly due to disease progression, the AE  causing the death should be 
reported to the study monitor as an SAE within [ADDRESS_797589]- mortem results (with  translation of 
impo rtant parts into English) shall be reported , if possible, to the sponsor. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 72 of 103  
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS]. Assessment of the Severity of Adverse Events  
The severity (toxicity grade) of AEs will be graded according to the NCI CTCAE, 
Version  4.03 (see Appendix 1) . 
[IP_ADDRESS]. Assessment of the Causal Relationship of Adverse Events to Study Drug 
The i nvestigator will assess causal relationship between study drug and each Adverse Event 
and classify each AE as either related  or unrelated. In determining if an AE is study drug 
related, the Investigator shall take into account the following question: “ Is there a reasonable 
possibility that the event may have been caused by [CONTACT_5257] ?” Investigators sh all use 
their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an adverse event is considered to be related  or unrelated  to study drug. The following guidance shall be taken into 
consideration when determining causality: 
• Temporal relationship of event onset to the initiation of study drug 
• Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable) 
• Known association of the event with the study drug or with similar treatments 
• Known association of the event with the disease under study  
• Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event  
• Presence of non -treatment- related factors that are known to be associated with the 
occurrence of the event  
The following terms for assessment of the causality to study drug or study procedures are to 
be used: 
• Unrelated : There is not a temporal relationship to study drug administration (eg, too 
early, too late, or study drug not taken), or there is a reasonable causal relationship between another drug, concurrent disease, or circumstance and the AE.  
• Related : There is a reasonable causal relationship between the study drug and the 
AE. The event responds to withdrawal of study drug, and recurs with re- challenge, 
when clinically feasible.  
 
For patients receiving combination therapy, causality wi ll be assessed individually for each 
study drug. 
[IP_ADDRESS]. Assessment of the Outcome of Adverse Events  
The outcome will be assessed accord ing to the following: 
• Fatal  
• Not recovered/not resolved 
• Recovered/resolved with sequelae  
• Recovering/resolving 
• Recovered/resolved  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 73 of 103  
G1 Therapeutics CONFIDENTIAL  • Unknown 
[IP_ADDRESS]. Method, Frequency, and Time Period for Detecting Adverse Events and 
Serious Adverse Events  
Adverse events and SAEs  are reported following the first dose of study drug through [ADDRESS_797590] dose of study drug (ie , the Post-Treatment  Visit ). 
[IP_ADDRESS]. Documentation of Adverse Events and Serious Adverse Events 
All AEs will be documented in the appropriate section of the eCRF. The CTCAE , 
Version  4.[ADDRESS_797591] in categorizing and 
grading AEs. A ll SAEs (see Section [IP_ADDRESS]) will be additionally  documented on the SAE 
report form .  
[IP_ADDRESS]. Adverse Event Coding 
Adverse event verbatim terms provided by [CONTACT_89824] G1 Therapeutics or its designee using the latest version of the MedDRA as specified in the statistical analysis plan (SAP).  
[IP_ADDRESS]. Reporting of Serious Adverse Events 
The reporting period for SAEs begins from the time of first dose of study drug through and 
including [ADDRESS_797592] be completed within 24 hours and faxed to the number below. 
[COMPANY_003] Pharmacovigilance: 
 
North America  
 
24 hour Safety P hone: 1 -[PHONE_5724] 
24 hour Safety Fax: 1- [PHONE_2421] 
 
EMEA/APAC   
 
24 hour Safety Phone :   [PHONE_046] 
24 hour Safety   Fax:  [PHONE_047]       
 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 74 of 103  
G1 Therapeutics CONFIDENTIAL  [IP_ADDRESS]. Follow-up of Adverse Events 
All AEs (both serious and nonserious) will be followed up in accordance with good medical 
practice until resolution, return to baseline, or it is deemed that further recovery is unlikely. All measures required for AE management and the ultimate outcome of the AE will be recorded in the source document and reported to the sponsor. 
All unresolved AEs should be followed by [CONTACT_941] i nvestigator until the events are resolved, the 
patient  is lost to follow -up, or the AE is otherwise explained , or further recovery is not 
deemed to be feasible. At  the last scheduled visit, th e investigator should instruct each patient  
to report any subsequent event(s) that the patient , or the patient’s personal physician, believes 
might reasonably be related to participation in this study.  Prior to the conclusion of the study at the site , the investigator should notify the medical 
monitor of any S AE occurring at any time after a patient  has discontinued or terminated 
study participation that may reasonably be related to the study drug. While the study is 
ongoing, all deaths should be reported via the electronic data capture system  regardless of 
relationship to study drug, even if the patient has discontinued participation in the study. 
After study conclusion, the investigator should notify the sponsor of any death or SAE they 
are aware of occurring at any time after a patient has discontinued or terminated study participation that may reasonably  be related to the study drug. The sponsor should also be 
notified if the investigator should become aware of the development of cancer or of a congenital anomaly in a subsequently conceived offspring of a patient that has participated in this study. 
[IP_ADDRESS]. Regulatory Aspects of Adverse Event Reporting 
The sponsor or its representative will report the following suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) to the independent ethics committee ( IEC)/institutional review 
board (IRB) in an expedited time frame:  
 
• S[LOCATION_003]Rs that have arisen in the current clinical study  that was assessed by [CONTACT_12137]/IRB  
 The sponsor or its representative will report all S[LOCATION_003]Rs to the Competent Authority, the Medicine Evaluation Board, and the Competent Authorities in other Member States, if applicable in an expedited time frame.  S[LOCATION_003]Rs that are already reported to the European Medicines Agency Eudravigila nce 
database do not have to be reported again to the Competent Authority and the Medicine Evaluation Board because they have direct access to the Eudravigilance database.  
 The expedited reporting will occur no later than [ADDRESS_797593] knowledge of the adverse reactions. For fatal or life- threatening cases the term will be a 
maximum of 7 calendar days for a preliminary report with another 8 days for completion of the final report. The investigator is encouraged to discuss with the medical monitor any adverse experiences for which the issue of reportability is unclear or questioned.   
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 75 of 103  
G1 Therapeutics CONFIDENTIAL  It is important that the investigator provide his/her assessment of relationship to study drug at 
the time of the initial report. 
[IP_ADDRESS]. Handling of Overdose 
In the context of a clinical study, an overdose is any dose which exceeds the daily dose that is 
defined in the clinical study protocol.  
If an overdose on a study drug occurs in the course of the study, then the i nvestigator or other 
site personnel shall  inform the appropriate sponsor representatives immediately, or no later 
than [ADDRESS_797594] reporting timelines apply, see 
Section  [IP_ADDRESS]. 
G1T38 
A maximu m tolerated dose of G1T38 has not been established. 
There is no specific treatment in the event of G1T38 overdose, and symptoms of overdose 
are not established. In the event of an overdose, physicians should follow general supportive measures and should tr eat symptomatically.  
Osimertinib  
A maximum tolerated dose has not been established for osimertinib.  
Such overdoses should be recorded as follows:  
• An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the eCRF and on the Overdose e CRF module  
• An overdose without associated symptoms is only reported on the Overdose e CRF 
module  
There is no specific treatment in the event of osimertinib overdose, and symptoms of 
overdose are not established. In the event of an overdose, physicians should follow general 
supportive measures and should treat symptomatically. 
[IP_ADDRESS]. Reporting of Pregnancies  
Pregnancy is not considered an AE unless there is cause to believe that the investigational 
drug may have interfered with the effecti veness of a contraceptive medication. Congenital 
abnormalities/birth defects and spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs.  Hospi[INVESTIGATOR_14494] a healthy newborn should not be considered a SAE. 
Each pregnancy, including ectopic pregnancy, which occurs during the course of the study 
and within [ADDRESS_797595] be discontinued immediately. 
The pregnancy should be followed up to determine outcome, including spontaneous or 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 76 of 103  
G1 Therapeutics CONFIDENTIAL  voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications and documented, even if the subject was discontinued from the study. 
The avoidance of pregnancy or fathering a child (including sperm donation) is recommended 
for [ADDRESS_797596]’s partner is not considered to be an AE. No information is currently available regarding the eff ects of 
G1T3 [ADDRESS_797597]’s partner consent must be obtained to collect information related to the pregnancy and outcome; the male subject should not be asked to provide this information. A consent 
form specific to this situation must be used. The outcome of any conception occurring from 
the date of the first dose until 4 months after dosing ends should be followed up and documented.  
10.6.2. Clinical Laboratory Assessments  
Blood samples will be collected for clinical laboratory assessments as outlined in  Table  9-1 
(Part 1) and Table  9-2 (Part 2). Hematology, clinical chemistry, and urinalysis samples may 
be obtained up to [ADDRESS_797598] treatment with study drug as long as the patient 's clinical 
condition has not changed. After baseline assessment (Day -16 in Part 1, Cycle 1 Day 1 in Part 2), C ystatin C shall be evaluated only in the event that the serum creatinine is elevated.  
The measurement of Cystatin C to estimate glomerular filtration rate is included in this study because G1T38 may i nhibit MATE transporters in the renal tubule and induce a 
nonpathologic increase in serum creatinine. The clearance of Cystatin C  is not dependent 
upon the MATE transporters and thus can help differentiate the effect of G1T38 on the MATE transporter from a true decline in renal function.  
Absolute neutrophil counts will be monitored weekly for the first 8 weeks (2 cycles), then every 2 week s for the next 2 cycles. Beginning with Cycle 5  Day 1, patients with stable 
≤ Grade [ADDRESS_797599] hematology monitored monthly on Day 1 of 
each cycle; patients that do not meet this criteria will continue to have every other week assessment of hematologic parameters.  
Clinical chemistry  will be monito red every [ADDRESS_797600] 4 cycles. Beginning with 
Cycle 5 Day 1, c linical chemistry will be monito red monthly on Day 1 of each cycle.   
Clinical laboratory tests to be performed are presented in Table 10-5.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797601]  
Lactate dehydrogenase  
Sodium  
Blood urea nitrogen/urea 
Cystatin C
a 
Urinalysis  
Specific gravity  
pH 
Glucose  
Protein  
Bilirubin  
Ketones  
Leukocytes  
Hem oglobin  
Microscopic examination (including RBC, WBC, 
and casts will be performed, if necessary)  Pregnancy  test 
Blood or urine tests are acceptable based on the site’s 
standard clinical practice; 
applicable to women of childbearing potential only.   
ALT = alanine aminotransferase; AST = aspartate aminotransferase; RBC = red blood cell; WBC = white blood cell 
a Postbaseline Cystatin C to be evaluated in the event that serum creatinine is elevated  
 
If treatment is interrupted, the patient should still complet e all clinical laboratory assessments 
as scheduled, as well as on the actual dosing day when treatment is reinitiated .  
Laboratory parameters shall be analyzed by a local certified laboratory and a report of the 
laboratory values sha ll be sent to the study  center. The investigator sha ll review the 
laboratory report promptly after receipt of the results and indicate the clinical significance of 
all abnormal values, and subsequently sign and maintain the laboratory report with the 
patient ’s source records/charts. Laboratory parameters for which clinically significant values 
are noted sha ll be re -measured on the appropriate clin ical follow -up arranged by [CONTACT_1275]. Any laboratory value that remains abnormal at the end of the study an d that is 
considered clinically significant sha ll be followed according to accepted  medical standards 
for up to 30 days or until resolution of the abnormality, or it is deemed that recovery is not 
feasible. 
Laboratory toxicities  shall be assessed using the NCI CTCAE , Version  4.03 (see 
Appendix 1).  
Laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE or SAE as described in Section 10.6.1.  
The SMC /IDMC  may modify the frequency of laboratory monitoring based on cumulative 
safety data.   
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 78 of 103  
G1 Therapeutics CONFIDENTIAL  10.6.3. Demographics and Vital Signs  
The following will be collected  at the time points outlined in Table  9-1 (Part 1) and Table  9-2 
(Part 2): 
1. Height in centimeters (cm)  
2. Body weight in kilogram (kg) 
3. Body temperature (Celsius) 
4. Systolic and diastolic blood pressure, pulse rate, and respi[INVESTIGATOR_1487]; b lood pressure 
should be assessed aft er [ADDRESS_797602] and should be assessed predose 
10.6.4. Physical Examination  
Physical examinations will be performed at the time points outlined in Table  9-1 (Part 1) and 
Table  9-2 (Part 2). 
Full physi cal examination evaluations at screening and the Post -Treatment visit shall include 
general appearance, skin, neck, eyes, ears, nose, throat, lungs /respi[INVESTIGATOR_696] , 
heart /card iovascular , abdomen, back, lymph nodes, thyroid, musculoskeletal (including spi[INVESTIGATOR_336301] ), and neurological examinations. Subsequent physical exams shall  be 
symptom directed and include body systems as appropriate.  
Clinically significant findings  on physical examination prior to administration  of the first 
dose of study drug must be recorded as medical history in the eCRF. Clinically significant 
findings on physical examination made after the first dose of study drug, which meet the 
definition of an AE, must be recorded as an  AE in the eCRF . 
10.6.5. Electrocardiogram  Assessments  
All patient s will have  three 12- lead ECGs performed at the visits  indicated in Table  9-1 
(Part 1) and Table  9-2 (Part 2).   
Part 1 ECG requirements  are as follows:  
Cycle and D ay  Time Points  
Screening  Anytime during visit (one set of 3 ECGs)  
Cycle 1 Day -16 Predose and at 2 and 6 hours (± 1 5 minutes) after 
the G1T38 dose  
Cycle 1 Day -2 Predose  and at 2 and 6 hours (± 1 5 minutes) after 
the G1T38 dose  
Cycle 2 Day 1 and Day 1 of each cycle thereafter  Anytime during visit (one set of 3 ECGs)  
 
Patients enrolled in Part [ADDRESS_797603] 
10 minutes prior to times indicated and should be recorded at 25 mm/sec. All ECGs shall  be 
recorded with the patient in the same physical position. The three ECG recordings shall  be 
taken within an approximate 5 minute period. A standardized ECG machine sh all be used 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797604] if appropriate. A paper copy should be 
filed in the patient’s medical records. If an abnormal ECG finding at screening or baseline is considered to be clinically significant by [CONTACT_093], it must  be reported as a concurrent 
condition. For all ECGs, details of rhythm, ECG intervals, and an overall evaluation will be 
recorded.  
ECG data sha ll be collected digitally and shall be transferred electronically for central 
analysis. The investigator may choose to perform a nondigital ECG at the time of the 
screening visit in order to identify patients eligible for study entry. If a nondigital ECG is 
performed at the screening visit it cannot subsequently be used as a baseline recording, in this situation an ECG will need to be collected on the baseline visit in digital form.  
Heart rate, PR, R -R, QRS , and QT intervals will be determined and reviewed during central 
analysis by [CONTACT_602420].  
If there is a clinically significant a bnormal ECG finding during the T reatment Phase, thi s 
should be recorded on the AE eCRF, according to standard AEs collection and reporting 
processes. A 30 -day follow- up assessment will be required if an on treatment assessment was 
abnormal at the time of discontinuation of study therapy, to confirm reversi bility of the 
abnormality.  
The investigator or designee sh all review the ECGs for any abnormalities as compared with  
the baseline ECGs.  
10.6.6. Ophthalmic Examination 
Full ophthalmic assessment, including sl it-lamp examination, shall  be performed at screening 
and if a patient experiences any visual symptoms (including blurring of vision), with 
additional tests if clinically indicated  (Table  9-1 [Part 1] and Table  9-2 [Part 2]) . 
Ophthalmology examination results shall  be recorded  in the eCRF.  
Any clinically significant findings, including those confirmed by [CONTACT_602421]. Photographs should be performed to record any clinically significant 
findings. These photographs should be available for central review by [CONTACT_602422].  
Patients experiencing corneal ulceration will not be permitted to restart study treatment.   
10.6.7. Echocardiogram/MUGA 
An e chocardiogram/MUGA scan to assess LVEF  shall  be performed at the time points 
outlined in Table  9-1 (Part 1) and  Table  9-2 (Part 2). The  modality of the cardiac function 
assessments must be consistent throughout the study for an individual patient (ie, if 
echocardiogram is used for the screening assessment then echocardiogram shall also be used for subsequent scans). The patient s shall also be examined using the same machine and 
operator whenever possible. A 30-day (+10 days) follow- up assessment will be required if an 
on treatment assessment was abnormal and clinically significant at the time of discontinuation of study therapy, to confirm reversibility of the abnormality.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797605]’s consent to the use of donated biological samples is mandatory. 
10.8. Appropriateness of Measurements  
The measures of efficacy , PK, and safety evaluated in this study are based on the mechan ism 
and activity of G1T38 and standard types of assessments typi[INVESTIGATOR_602396]. The measure ment  of tumor response based on the RECIST, V ersion  1.1 
(Eisenhauer  2009)  is standard. The PK and safety measu res included in this study are also 
standard.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 81 of 103  
G1 Therapeutics CONFIDENTIAL  11. STUDY TERMINATION OR STUDY DRUG 
DISCONTINUATION  
11.1. Study Termination  
The entire study may be terminated in the event of any of the following: 
• Occu rrence of AEs unknown to date with respect of their nature, severi ty, and duration, 
or the unexpected incidence of known AEs 
• Medical or ethical reasons affecting the continued performance of the study  
• Difficulties in the recruitment of patients  
• Cancellation of the drug development program 
• Sponsor decision for other reasons  
 
11.2. Site Termination  
A study site may be closed if there is evidence of fraud, other unethical conduct, or 
significant regulatory non complianc e to the protocol or to Good Clinical Practice (GCP ), or 
if insufficient patients have been enrolled to meet  the site objectives.  
11.3. Discontinuation of Study Drug  
Study drug(s)  shall  be discontinued if any of the following events occur during the study: 
• A patient suffers an AE  that, in the judgment of the investigator, sponsor, or medical 
monitor, presents an unacceptable risk to the patient (see Section  [IP_ADDRESS] for 
additional details).  
• General or specific changes in the patient’s condition (eg, a significant intercurrent 
illness or complication)  that, in the judgment of the investigator, are unacceptable for 
further administration of study drug 
• Occurrence of pregnancy 
• Significant noncompliance with protocol requirements  
• The s ponsor or legal representative of the sponsor reque sts the patient to withdraw  
• Patient has radiographically documented or clinically determined disease progression, 
with the exception of patients in Part 2  that crossover  from  osimertinib alone  to 
G1T38 + osimertinib at the time of disease progression . 
In the event of study drug discontinuation, patients sh all be strongly encouraged to complete 
all scheduled assessments; the Post -Treatment Visit; and the Survival Follow -up Phase of the 
study. A patient who discontinues study drug for reasons other than P D shall  have a CT or 
MRI scan at the Post -Treatment  Visit , if they have not had a scan within the prior [ADDRESS_797606]- treatment scans.  
When discontinuation is due to a SAE or a Grade 3 or 4 toxicity considered to be related to study drug, the investigator shall  follow the event until resolution, return to baseline, or it is 
deemed that further recovery is unlikely.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 82 of 103  
G1 Therapeutics CONFIDENTIAL  In the event a patient discontinues due to an AE or pregnancy, the investigator shall  notify 
the medical m onitor or [COMPANY_003] Safety Services by [CONTACT_16470] 24 hours of study drug 
discontinuation. 
11.4. Withdrawal of Patients from the Study  
Patients may withdraw from the study at their own discretion (or at the discretion of the 
investigator) for any reason at any time.  
All data and lab samples collected prior to the date of withdrawal of consent will remain in 
the clinical database and at lab oratory  vendor.  
 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 83 of 103  
G1 Therapeutics CONFIDENTIAL  12. STATISTICS  
Full details on the statistical analyses to be performed will be provided in a sepa rate 
Statistical Analysis Plan ( SAP). 
12.1. Sample Size and Power  
It is estimated that up to 36 patients will be enrolled in the dose -escalation part of the study 
(Part 1). The actual number of patients will depend on the number of dose levels/cohorts that 
are tested.   
For the randomized part of the study (Part 2),  it is assumed that  the overall 1- sided type I 
error rate is 0.1 and the type II error rate used to compute sample size is 0.20 (corresponding to 80% power). Patients will be randomized using a 1:1 treatment allocation ratio between 
the 2 treatment groups ( osimertinib  versus G1T38 + osimertinib).  
Assuming a 10.1 month median PFS for the osimertinib group from historical data 
(Mok et  al, 2017) and a hazard ratio (HR) of 0.6 (corresponding to a median PFS of 
16.8 months for the G1T38 + osimertinib  group), the required number of PFS events is 70. 
Assuming an accrual period of [ADDRESS_797607] patient is enrolled, the calculated total sample size for Part 2  is 98 patients. 
Allowing for a dropout/ lost- to-follow -up rate of approximately 10% gives an adjusted total 
sample size of 108.  
These calculations were carried out using the PO WER procedure in SAS
® Version 9.4. 
12.2. General Considerations 
12.2.1. Analysis Populations  
The safety analysis set will include all enrolled patients who were administered at least 
1 dose of study drug. All safety analyses will be assessed using the safety analysis se t. 
Analyses using the safety analysis set will be conducted on the basis of the actual treatment received.  
The full analysis set (FAS) includes all patients who received at least [ADDRESS_797608] postdose tumor scan. The 
response evaluable analysis set will be used for analyses of tumor response and PFS.  
The per- protocol (PP) analysis set will include all patients in the safety analysis set who have 
no major protocol deviations and who received the treatment to which they were randomized. 
For patients who took the wrong treatment for Part 2 of the study, their data will be excluded from the PP analysis set. The PP analysis set may be used to analyze selected endpoin ts to 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797609] the robustness of results. The criteri a for inclusion in the PP analysis set  will be finalized 
and documented prior to database lock. 
The PK analysis set  will include all dosed patients with evaluable PK data ; it will be the basis 
of PK -related summaries .  
12.2.2. Timing of Analyses  
[IP_ADDRESS]. Interim Safety Reviews  
Following completion of data collection for each dose cohort of Part 1, the SMC  will review 
all safety and available PK data in order to determ ine the subsequent dose level. At the end of 
Part 1 of the study, the SMC will review all cumulative safety and PK dat a in order to 
determine the RP2D.  
[IP_ADDRESS]. Independent Data Monitoring Committee 
During Part 2, an IDMC will evaluate accumulating safety data according to a charter that 
defines its roles and responsibilities. The I DMC will perform interim reviews approximately 
every [ADDRESS_797610] of individuals with extensive multicenter clinical study experience drawn from the fields of clinical oncology (specifically, NSCLC) , clinical 
pharmacology, and biostatistics. These individuals will be entirely independent of the conduct of the study. 
Additional details regarding the committee procedures and policies, including table displays, 
will be described in the I DMC charter.  
[IP_ADDRESS]. Final Analysis  
The final analysis will utilize data obtained by [CONTACT_602423] 70 PFS events (65%) have occurred or [ADDRESS_797611].  
 [IP_ADDRESS]. End of Study Analysis 
The Survival Follow- up Phase will continue until at least 50% of the patients in Part [ADDRESS_797612] 
died. If the Follow -up Survival Phase of the study continues after the final analysis, a 
supplementary analysis will be done at the time of study completion. Reported results will be cumulative in nature, including all data collected during the entire study. 
12.2.3. General Considerations for Data Analysis  
Detailed methods of statistical analyses will be presented in the SAP. All statistical analyses 
will be performed using SAS
® Version 9 or higher.  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 85 of 103  
G1 Therapeutics CONFIDENTIAL  In general, data will be summarized separately by [CONTACT_16051] (Part 1 and Part 2). Data from 
Part 1 will be su mmarized descriptively by [CONTACT_15994], if applicable, and overall. Data from 
Part 2 will be summarized descriptively by [CONTACT_6654]. Treatment differences between treatment groups for Part 2 will be calculated as G1T38 + osimertinib minus os imertinib alone. Selected safety summaries will include combined data from both 
Parts [ADDRESS_797613] 
deviation (StD), and minimum and maximum values. The descriptive summaries of 
time-to-event data will include median, 25% and 75% percentiles, and standard error. The 
Kaplan -Meier method will also be used to summarize the t ime-to-event data. All data will be 
listed for all patients.  All confidence intervals ( CIs) for treatment differences between 
treatment groups for Part 2 will be 2-sided 80%, and other CIs will be 2-sided 95%, unless stated otherwise.  
Part 1 of the study is descriptive in nature. For the Part 2 of the study, all statistical tests will 
be conducted at a 1- sided significance level of 10% unless otherwise specified 
(G1T38 + osimertinib  versus osimertinib alone ). Where appropriate, model based point 
estimates, together with their 80% CIs will be presented along with the 1-sided p-value for the test.  
12.3. Part 1 (Phase 1b) Statistical Analyses  
The primary analysis is based on the assessment of safety and tolerability endpoints for 
Part 1 of the study. The data will be analyzed by [CONTACT_9086]. All CIs of data 
summary will be 2 -sided 95%, unless stated otherwise.  
Adverse event data will be coded to system organ class and preferred term using MedDRA (Version 17.1 or later). The number and percentage of patients experiencing any TEAE, overall, and by [CONTACT_89794]. Adverse events related to treatment will be further summarized by [CONTACT_602424] (eg, G1T38 or osimertinib). DLTs and withdrawals due to AEs will be summarized or listed; further details with respect to these events can be found in Section [IP_ADDRESS]  and 11.3. Severity 
will be tabulated based on greatest severity observed for each patient. If a patient experiences an AE more than once during the study, the greatest severity will be tabulated.   Any AE occurring within the defined [ADDRESS_797614] dose of study drug will be included in the AE summaries. Any adverse events in this period that occur after a patient has received further ther apy for cancer (following discontinuation of study drug) 
will be flagged in the data listings. AEs occurring after the [ADDRESS_797615] dose of study drug will be listed separately, but not included in the summaries. 
12.3.1. Other Safety Endpoints  
Observed values and changes from baseline in vital signs, ECG readings, 
echocardiogram/MUGA  scan  results, and hematology, clinical chemistry , and liver function 
parameters will be tabulated at each visit. Toxicities for clinical labs will be characterized 
according to CTCAE, Version 4.03. Shifts in toxicity grades from baseline to each visit, and 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797616] time, concentration or shift plots. For example, graphical presentations of average changes over time will provide additional focus to be placed on neutrophils and platelet data. 
Dose reductions/modifications, interruptions, compliance, and 
patient  exposure will be 
summarized for each study therapy component, where appropriate.  
12.3.2. Efficacy Endpoints 
Antitumor efficacy endpoints include the following: 
• Best overall response (BOR) according to RECIST v1.1  
• Objective response (OR) (CR or PR) according to RECIST v1.1  
• Duration of OR, and time to first objective response accordi ng to RECIST v1.1  
• Clinical benefit rate (CBR) according to RECIST v1.1  
• Progression- free survival (PFS) according to RECIST v1.1  
• Overall survival (OS) 
BOR will be determined using visit responses up until the last evaluable overall visit 
response prior to or on the date of (i) radiographic or clinical disease progression ; (ii) 
withdrawal of consent to obtain scans; or (iii) receiving subsequent anti cancer therapy, 
whichever is earlier. At each tumor assessment visit, an overall time point response by 
[CONTACT_393] 1.[ADDRESS_797617] objective response is only derived from assessments up to and including the time of the progression (ie , it will 
not include the response after the patient has progressed).  
When the minimum interval for confirmation o f CR and PR is not satisfied or if there are no 
confirmatory scans for CR and PR for a patient, then [ADDRESS_797618]  1.1, which requires co nfirmation of CR and PR; in the other method, 2 or more 
response categories will be added as unconfirmed CR and unconfirmed PR. Both ways of 
assigning BOR will be implemented in the analysis.   
Objective res ponse will be derived as No/Yes (0/1) variable. Patients with a BOR of 
confi rmed CR or PR will be assigned “Yes”. Patients not having a BOR of confi rmed CR or 
PR will be assigned “No .” Hence, objective response rate (ORR) is defined as the proportion 
of patients with objective response being “Yes .”  
Clinical benefit rate (CBR) is defined as the proportion of patients with a BOR of confirmed 
CR or confirmed PR or SD at the 8 week (end of Cycle 2) or later assessment . A patient will 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797619] date of study drug administration.   
Duration of Objective Response (DOR) is the time between first objective response of CR or 
PR and the first date that progressive disease is objectively documented or death. Patients who do not experience objective PD or death will not be included in the analysis.  
Time to first objective response is the time from first dose of study drug to first objective 
response of CR or PR. Patients who do not experience objective response of CR or PR will be censored at the last adequate assessment date.  
PFS is defined as the time (number of months) from date of first dose of study drug until date 
of documented disease progression or death due to any cause, whichever comes first. More specifically, PFS will be determined using all the assessment data up until the last evaluable visit prior to or on the date of (i) radiographic or clinical disease progression; (ii) withdrawal 
of consent to obtain scans; or (iii) receiving subsequent anti cancer therapy, whichever is 
earlier. Death is always categorized  as a confirmed PD event. Censoring methods for patients 
who do not experience PD or death will be described in the study SAP. 
OS is calculated as the time (number of months) from date of first dose of study drug to the 
date of death due to any cause. Patients who do not experience fatalities during the course of the study will be censored at the date last known to be alive. Patients lacking data beyond the day of first dose of G1T38 will have their survi val time censored at day of first dose. OS will 
not be censored if a subject receives other  antitumor treatments after the study drugs.   
The BOR, ORRs, and CBR and their corresponding 95% exact CIs will be calculated by [CONTACT_94532]-Pearson method. DOR, time to first objective response, PFS, and OS will be analyzed based on time- to-event summary method. For PFS and OS, Kaplan- Meier estimates 
will be plotted and tabulated at selected landmark time points (ie,  6 months, 1 year, 1.5 years, 
and 2 years).   
12.4. Part [ADDRESS_797620]  1.1. Other antitumor efficacy endpoints include the following: 
• BOR according to RECIST 1.1  
• OR (CR or PR) according to RECIST 1.1 
• Duration of OR, and time to first objective response according to RECIST 1.1 
• CBR according to RECIST v1.1  
 
The derivation of these endpoints follows the similar practice as described in Section  12.3.2, 
except for the following: 
• For the CBR, a patient will be considered to have SD  if an  SD response is recorded at 
the 8 week (end of Cycle 2) or later assessment  from the date of randomization  
• Both PFS and OS are meas ured from date of randomization 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 88 of 103  
G1 Therapeutics CONFIDENTIAL  • For those patients who have cross ed over from osimertinib to G1T38 + osimertinib in 
Part [ADDRESS_797621] dose of G1T38 administered during the crossover period will be 
utilized as a reference da ta for endpoint derivations  
 
Because patients who progressed on osimertinib alone are allowed to crossover to G1T38 + 
osimertinib, there will be 4 types of summaries for PFS and other antitumor efficacy endpoints ( with the first one being the primary source) as follows: 
1. Summaries and listings based on assessments collected in the randomized portion
 of the 
study (ie, A versus B  + D in Figure 12-1) .   
2. Summaries and listings based on assessments collected in the randomized portion  of the 
study (ie, A versus D in Figure 12-1 ).  
3. Summaries and listings based on assessments collected in the randomized portion  of the 
study for the G1T38 + osimertinib group and crossover portion for the osimertinib alone  
group (ie, A versus C in Figure 12-1 ). 
4. Summaries and listings based on assessments collected in the crossover portion (ie, 
C alone in Figure 12-1 ). 
Figure 12-[ADDRESS_797622], stratified by 
[CONTACT_602425] (yes versus n o) and ethnicity (Asian versus non- Asian), will be 
used to test the null hypothesis that the distributions in the [ADDRESS_797623] for treatment arm and stratification factors will be 
used to estimate the HR and its 80% CI. Kaplan- Meier estimates will be plotted and tabulated 
at selected landmark time points (ie,  6 months, 1 year, 1.5 years, and 2 years). The median 
value and a 95% CI will also be provided (assuming the median can be estimated).   
For the overall tumor response data such as ORR and CBR, the 1- sided stratified CMH  test 
will be used to compare the 2 treatment groups. The odds ratio and its associated 80% CI will be pr esented.  
Patients who progressed on osimertinib alone are allowed to crossover to G1T38 + osimertinib. Despi[INVESTIGATOR_602397], the primary analysis of OS (ie,  A versus D + (B + 
C) in  Figure 12-1)  will use the strict intention -to-treat (ITT) approach based on FAS, ie, 
“analyze as randomized” and ignore the treatment switch following progress ion (and ignore 
additional anti cancer therap ies administered after study drug discontinuation). This approach 

G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797624]. However, osimertinib  patients who switch to G1T38 + 
osimertinib after disease progression may benefit from the delayed administration of G1T38; 
therefore, the sur vival treatment estimate becomes confounded. Under such circumstances, 
the statistical test of the treatment effect is known to be biased towards the null hypothesis of 
no difference ( Robins and Tsiatis 1991; Korhonen et al 1999 ; Greenland et al 2008 ). 
Therefore, [ADDRESS_797625] corrected for treatment cross over: r ank-preserving structural failure 
time (RPSFT)  method and Cox model with inverse probability of censoring weighting 
(IPCW). More detailed information will be provided in SAP.  
In terms of OS, there will be 3 additional types of summaries as follows:  1. Summaries and listings based on assessments collected in the randomized portion
 of the 
study (ie, A versus D in Figure 12-1 ) 
2. Summaries and listings based on assessments collected in the randomized portion  of the 
study for group of G1T38 + osimertinib and crossover portion for group of osimertinib 
alone (ie,  A vers us C in Figure 12-1 ) 
3. Summaries and listings based on assessments collected in the crossover portion (ie, C alone in Figure 12-1 ).  
Moreover, post progression survival will be evaluated for A versus D and C versus D in 
Figure 12-1, and it is calculated as the time (number of months) from the date of first 
documented progression to the date of death due to any cause, or to the date of last contact (censored observation). For patients who progress on osimertinib alone and crossover to G1T38 + osimertinib, the date of first documented progression on osimertinib alone will be used for the analysis. Patients without documented progression will be excluded from the post progr ession survival analysis.     
In addition, potential influences of baseline patient characteristics such as age, ECOG performance status, and selected biomarkers on the endpoints may be evaluated to compare the treatment groups.   
12.4.1. Safety evaluation  
The assessment of safety will be ba sed mainly on the frequency of TEAEs and on the number 
of laboratory values that fall outside of pre determined ranges according to CTCAE, 
Version  4.03. Other safety data (eg, ECG , vital signs, and echocardiogram/MUGA scan 
result s) will be considered as appropriate.   
 
Dose reductions/modifications, interruptions, compliance, and patient exposure will be summarized for each study therapy component, where appropriate. 
Since patients who progressed on osimertinib alone are allowed to crossover to G1T38 + 
osimertinib, there will be 3 types of safety summaries ( with the first one being the primary 
source of safety assessment)  as follows:  
 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 91 of 103  
G1 Therapeutics CONFIDENTIAL   

G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797626] the investigator’s records by [CONTACT_11200] (source document 
verification), and the maintenance of a drug- dispensing log. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797627]  Statement  
The investigator will ensure that this study is conducted in full confor mance with the 
principles of the Declaration of Helsinki (as amended in Tokyo, Venice, Hong Kong, and 
South Africa) or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The investigator will ensur e adherence to the basic prin ciples of GCP  as outlined in the current version of 21 Code 
of Federal Regulations ( CFR), subchapter D, part 312, Responsibilities of Sponsors and 
Investigators, part 50, Protection of Human Subjects, and part 56, Institutional Review Boards, a nd ICH E6 GCP . The investigator will follow all national, state, and local laws of 
the pertinent regulatory authorities.  
14.2. Independent Ethics Committee /Institutional Review Board  
The protocol and all associated amendments and consent/assent materials will be reviewed and approved by [CONTACT_3878]’s local IEC/IRB  or a central IEC /IRB . It is the 
investigator’s responsibility to obtain approval of the study protocol and informed consent, and any other study related materials such as advertising or i nformation leaflets , from their 
IEC/IRB  prior to initiating the study. Approval must be obtained in writing via a lette r 
identifying the protocol, the date of the IEC /IRB  meeting , and the date of approval. 
14.3. Informed Consent  
It is the responsibility of the investigator to obtain written informed consent from each patient  participating in this study, after adequate explanation of the goals , methods, potential 
benefits, and hazards of the study. The investigator or designee must also explain that the patient s are allowed  to withdraw from  the study at any time and for any reason. All patient s 
should be given a copy of the informed consent and any updates. Original signed consent form s will be maintained at the site and be made available for inspection, as appropriate.  
14.4. Patient  Confidentiality  
The investigator must assure that patient s’ anonymity will be maintained and that their 
identities are prote cted from unauthorized parties. Patient  nam es will not be supplied to the 
sponsor and only the patient number will be recorded in the eCRF and study findings stored on a computer will be stored in accordance w ith local data protection laws. The patient s will 
be inform ed that repre sentatives of th e sponsor, IEC/IRB , or regulatory authorities may 
inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data p rotection laws.  
14.5. Adherence to the Protocol  
The study shall be conducted as described in this protocol, except for an emergency situation in which proper care of the patient requires immediate alternative intervention. The protocol 
will be provided to the IEC/IRB  and appropriate local regulatory authorities for approval. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 94 of 103  
G1 Therapeutics CONFIDENTIAL  Any protocol amendments will be done in accordance with the provisions agreed upon in 
Section 14.6 . Any deviation from the design of the study as set forth in this document will be 
recorded as a protocol deviation and will be explained in detail as it occurs and/or is detected.  
14.6. Protocol Am endments  
All protocol amendments (both nonsubstantial and substantial amendments)  must be 
submitted to the appropriate IEC /IRB  and competent authorities (as required)  in accordance 
with local requirements. Approval for substantial amendments must be receiv ed in writing 
befor e changes can be implemented (ie, if the risk benefit ratio is affected and/or the 
modification represents a change in basic study definitions such as objectives, design, sample size, and outcome measures, etc. ), except for those changes which would decrease risk to the 
patient . 
14.7. Patient Compliance  
Patients must be available f or all scheduled study visits. Any reason for patient 
noncompliance will be documented . 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797628] the i nvestigator’s records by [CONTACT_11200] (source document verification), 
and the maintenance of a study drug- dispensing log by [CONTACT_941] i nvestigator.  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a sponsor 
representative will review the protocol and eCRFs with the i nvestigators and their staff. 
During the study, a monitor will visit the site regularly to check the completeness of patient  
records, the accuracy of entries o n the eCRFs , the adherence to the protocol and to GCP, and 
the progress of enrollment. The monitor will ensure during on- site visits  that study d rug is 
being stored, dispensed, and accounted for according to specifications. Key study personnel must be avai lable to assist the monitors during these visits.  
The i nvestigator must give the monitor access to relevant hospi[INVESTIGATOR_89787]. No information in these records about the 
identity of the patient s will leave the study center. Monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of primary efficacy  and safety variables.  
15.2. Investigator Reporting Requirements 
Local regulations may require the investigator to provide periodic safety updates on the conduct of the study and to notif y the IEC /IRB  of study closure. Such updates and 
notifications are the responsibility of the investigator.  
15.3. Records Retention  
After closure of the study, the investigator will maintain copi[INVESTIGATOR_89788] (ie, 
investigator files and patient files)  in a secure location. The investigator’s study file will 
contain the protocol, protocol amendments, e CRF and  query forms, IEC /IRB  and 
governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.  
Patient  clinical source documents may include (but not limited to) patient hospi[INVESTIGATOR_1097], 
physician's and nurse's notes, original laboratory reports, ECG, electroencephalogram , X-ray, 
signed informed consent forms, c onsultant letters, and patient screening and enrollment logs.  
These documen ts must be kept  on file by [CONTACT_1732] a period of 2 years following 
the date the marketing application is approved for the drug indication for which it is being 
investigated. If no application is to be filed or if the application is not approved for such 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated [ADDRESS_797629] notify the sponsor in the event of accidental loss or destruction of any study records and should notify the sponsor of an y 
reassignment of study records to another party or move to another location.  
15.4. Study Monitoring  
Qualified representatives of the sponsor or sponsor designees (study monitors ) will monitor 
the study according to a predetermined monitoring plan. The inve stigator must permit the 
study monitors to periodically review all eCRFs and source documents supporting the 
participation of each patient in the study. The eCRFs and other documentation suppo rting the 
study must be kept up to date by [CONTACT_16993] d the staff at the study site. These study 
materials must be available for  review by [CONTACT_1758] m onitor, and/or other qualified 
representatives of the sponsor, at each monitoring visit and must be provided in a way such that the patient ’s confidentiality is m aintained in accordance with local institution, state, 
country, and federal requirements.  
15.5. Audits and Inspections  
At some point during the study or after the study, appropriately qualified personnel from the 
sponsor’s Quality Assurance group, or their authorized representative, or a representative from a regulatory authority may visit the investigator to conduct an inspect ion of the study 
and the site. During this audit, the investigator agrees to give the audi tor direct access to all 
relevant documents supporting the eCRFs and other study-related documents and to discuss any findings with the auditor. In the event of an inspection by a regulatory agency, the 
investigator agrees to give the inspector direct access to all relevant documents and to discuss 
any findings with the inspector. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 97 of 103  
G1 Therapeutics CONFIDENTIAL  16. PUBLICATION POLICY 
By [CONTACT_33351], the investigator and his or her institution agree that the results 
of the study may be used by G1 Therapeutics for the purposes of national and international registration, publication, and information for medical and pharmaceuti cal professionals. If 
necessary, the authorities will be notified of the investigator’s name, address, qualifications, and extent of involvement. 
Initial pub lication of the results of this study will be of a cooperative nature that may include 
authors representing the sponsor, i nvestigator(s), and co llaborating scientists.  Independent 
publications by [CONTACT_89838]. Investigators and their ins titutions agree not 
to publish or publicly present any interim results of studies without the prior written consent 
of G1 Therapeutics. 
At least 60 days prior to expected submission to the intended publisher or meeting 
committee, the i nvestigator will submit a copy of the desired presentation (oral or written) or 
publication manuscript to the sponsor. This review period may be shortened upon mutual consent where circumstances require expeditious review. The s ponsor reserves the right to 
request modification of any publication, presentation or use by [CONTACT_941] i nvestigator if such 
activity may jeopardize a patent application, an existing patent, or oth er proprietary rights. 
The s ponsor shall determine order of authorship of any publication combining al l clinical 
results of this study. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 98 of 103  
G1 Therapeutics CONFIDENTIAL  17. REFERENCES  
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron. 1976;16:31- 41. 
Cristofanilli M, Turner N, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone- receptor -positive, HER2- negative metastatic breast 
cancer that progressed on previous endocrine therapy (PALOMA- 3): final analysis of the 
multicentre, double -blind, phase 3 randomised controlled trial. The Lancet Oncology. 2016; 
17(4):425-439. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer.  2009;45:228-247. 
Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent- to-treat design and G-estimation. Clinical Trials.  
2008;5: 5- 13. 
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribocicl ib as first- line therapy for 
HR-positive, advanced breast cancer. N Engl J Med. 2016;375: 1738-1748. 
Ko B, He T, Gadgeel S, Halmos B. MET/HGF pathway activation as a paradigm of resistance to targeted therapi[INVESTIGATOR_014]. Ann Transl Med. 2017;5(1):4. 
Korhonen P, Laird NM, Palmgren J. Correcting for non-compliance in randomized trials: an 
application to the ATBC study. Statistics in Medicine . 1999; 18: 2879-2897. 
Minari R, Bordi P, Tiseo M. Third-generation epi[INVESTIGATOR_3506]-tyrosine kinase inhibitors in T790M -positive non- small cell lung cancer: review on emerged 
mechanism of resistance. Transl Lung Cancer Res. 2016; 5(6):695-708. 
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR 
T790M- positive lung cancer. N Engl J Med. 2017;376: 629-640. 
Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochimica et Biophysica Acta- Reviews on Cancer.  2002; 1602(1):73-87. 
Prescribing information: Abemaciclib (Verzenio
®) 
http://uspl.lilly.com/verzenio/verzenio.html#pi  [INVESTIGATOR_602398]: Osimertinib (Tagrisso
®) 
https://www.azpi[INVESTIGATOR_24309].com/tagrisso/ta grisso.pdf#page=1 
Prescribing information: Palbociclib (IBRANCE®) 
http://labeling.pfizer.com/ShowLabeling.aspx?id=2191 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 99 of 103  
G1 Therapeutics CONFIDENTIAL  Prescribing information: Ribociclib (KISQALI®) 
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali.pdf 
Rama lingam SS, Yang JCH, Lee CK, et al. Osimertinib as first -line treatment of EGFR 
mutation -positive advanced non- small -cell lung cancer. J Clin Oncol . 2017;35. 
Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank 
preserving structural failure time models (RPSFTM). Commun. Statist.- Theory Meth . 
1991;20(8): 2609-2631. 
Sequist LV, Neal JW. Personalized, genotype-directed therapy for advanced non- small cell 
lung cancer. In: Lilenbaum, ed. UpToDate . Waltham, Mass.: UpToDate; 2017. 
www.uptodate.com. Accessed August 1, 2017. Shapi[INVESTIGATOR_76604]. Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of 
Clinical Oncology. 2006; 24 (11):1770-1783. 
  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 100 of 103   
G1 Therapeutics CONFIDENTIAL  18. APPENDICES  
APPENDIX 1:  Common Terminology Criteria f or Adverse Events 
(CTCAE) – Version  4.03 
The NCI CTCAE Version 4.03 (CTCAE 4.03 14 June 2010) can be accessed from the 
following National Cancer Institute (NCI) website:  
http://evs.nci.nih.gov/ftp1/CTCAE/About.html 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 
APPENDIX 2: Prescribing Information  for Osimertinib 
Tagrisso® (osimertinib) PI, March 2017  link:  
https://www.azpi[INVESTIGATOR_24309].com/tagrisso/tagrisso.pdf#page=1  
APPENDIX 3: Drugs that May Prolong the QT Interval  
The drugs listed in this section are taken from information provided by [CONTACT_602426], Tucson, Arizona 
and Rockville, Maryland. Ref: http://www.arizonacert.org/medical-pros/drug- lists/drug - 
lists.h
tm. 
Drugs Known to Prolong the QT Interval 
The following drugs are known to prolong QT interval or induce Torsades de Pointes and 
should not be combined with osimertinib. Recommended withdrawal periods following cessation of treatment with these agents are provided in Table 18-1. 
Table 18-1 Drugs Known to Prolong  the QT Interval  
Contraindicated Drug  Withdrawal Period Prior to Initiating 
Osimertinib  
Clarithromycin, droperidol, erythromycin, procainamide  2 days  
Cisapride, disopyramide, dofetilide, domperidone, ibutilide, 
quinidine, sotalol, sparfloxacin,  thioridazine  7 days  
Bepridil, chlorpromazine, halofantrine, haloperidol, mesoridazine  14 days  
Levomethadyl, methadone, pi[INVESTIGATOR_3924]  4 weeks  
Arsenic trioxide  6 weeksa 
Pentamidine  8 weeks  
Amiodarone, chloroquine  1 year  
a Estimated value as pharmacokinetics of arsenic trioxide has not been studied.  
Drugs that May Possible Prolong the QT Interval 
Use o f the drugs in Table 18-2 is permitted (notwithstanding other exclusions and 
restrictions) provided the patient has been stable on therapy for the periods indicated. 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 101 of 103   
G1 Therapeutics CONFIDENTIAL  Table 18-2 Drugs that May Prolong QT Interval 
Drug  Minimum Treatment Period on Drug 
Prior to Initiating Osimertinib  
Alfuzosin, chloral hydrate, ciprofloxacin, dolasetro n, foscarnet, 
galantamine, gemi floxacin, isridipi[INVESTIGATOR_050], ketocona zole, levo floxacin, 
mexilet ine, nicardipi[INVESTIGATOR_050], octreotide, o floxacin, ondanset ron, 
quetiapi[INVESTIGATOR_050], ranolazine, telithromycin, tizanidine, vardenafil, 
venlafaxine, ziprasidone  2 days  
Amantadine, amitriptyline, amoxapi[INVESTIGATOR_050], clozapi[INVESTIGATOR_050], doxepin, felbamate, flecainide, ibutilide, qui nidine, sotalol, sparfloxacin, 
thioridazine, 
fluconazole, fo sphenytoin, gatifloxacin, 
granisetron, imipramine, indapamide, lithium, 
moexipril/HCTZ, moxifloxacin, risperidone, roxithromycin, 
sertraline, trimethoprin- sulfa, trimipramine, voriconazole  7 days  
Azithromycin, citalopram, clomipramine, itraconazole, nortriptyline, 
paroxetine, solifenacin, tacrolimus  14 days  
Fluoxetine  5 weeks  
Protriptyline  6 weeks  
Tamoxifen  8 weeks  
 
APPENDIX 4:  Drugs Known to Interact with the  P-glycoprotein, 
BCRP, MATE1, MATE2 -K, and OCT1 and [ADDRESS_797630] with membrane transporters is a representative 
sample of potentially G1T38- interacting drugs.  Caution should be exercised if any of these 
drugs are concurrently used with G1T38. Use of strong inhibitors of BCRP is prohibited. 
Strong Inhibitors of P-gp (use with caution): 
• Cyclosporine 
• Elacridar  
• Ketoconazole 
• Reserpi[INVESTIGATOR_050]  
• Ritonavir 
• Tacrolimus 
• Valspodar 
• Verapamil  
• Zouquidar 
• Amiodarone 
• Carvedilol  
• Clarithromycin  
• Dronedarone 
• Itraconazole  
• Lapatinib  
• Propafenone 
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 102 of 103   
G1 Therapeutics CONFIDENTIAL  • Quinidine 
• Ranolazine 
• Telaprevir  
Strong Inhibitors of BCRP (use prohibited): 
• Elacridar  
• Fumitremorgin C  
• Ko134 
• Ko143 
• Novobiocin 
• Sulfasalazine 
• Curcumin 
• Cyclosporine A 
• Eltrombopag 
Strong Inducers of P-gp (use with caution): 
• Carbamazepi[INVESTIGATOR_050]  
• Phenytoin 
• Rifampin  
• St. John’s Wort  
• Tipranavir  
MATE1 and MATE2 -K Substrates (use with caution): 
• Metformin  
• MPP+  
• Tetraethylammonium (TEA) 
• Dofetilide  
OCT1 and OCT2 S ubstrates (use with caution): 
• OCT1: metformin, oxaliplatin, aciclovir, ganciclovir 
• OCT2: metformin, pi[INVESTIGATOR_8405], procainamide, ranitidine, amantadine, amiloride, oxaliplatin, 
varenicline, cisplastin, debrisoquine, proplanolol, guanidine, D-tubocurarine, 
pancuronium 
P-gp S ubstrates (use with cau tion): 
• Digoxin 
• Fexofenadine 
• Loperamide 
• Quinidine 
• Talinolol  
• Vinblastine 
• Dabigatran  
G1 Therapeutics  
Clinical Study Protocol G1T38 -03 G1T38 
 
Version: 4.0, dated 0 2 September  2019  Page 103 of 103   
G1 Therapeutics CONFIDENTIAL  BCRP S ubstrates (use with caution): 
• 2-amino -1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 
• Coumestrol 
• Daidzein  
• Dantrolene  
• Estrone-3- sulfate  
• Genistein  
• Prazosin  
• Sulfasalazine 
• Rosuvastatin  
APPENDIX 5:  RECIST Version 1.1 Time Point Response Evaluation 
Guidelines for Patients with Nontarget Disease Only 
 
Nontarget Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PDa 
Not all evaluated  No NE 
Unequivocal  PD Yes or No  PD 
Any Yes PD 
CR = complete response; NE = not evaluable; PD = progressive disease  
a Non-CR/non-PD is preferred over stable disease for nontarget disease since stable disease is increasingly used as 
endpoint for assessment of efficacy in some studies, so to assign this category when no lesions can be measured is not 
advised. 
Source: Table modified  from Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur  J Cancer. 2009;45:228-247. 
 
 
APPENDIX 6: Radiotherapy Guidance for Symptomatic Lesions  
 
• Palliative radiotherapy to control symptoms (including gamma knife technique), eg to 
control brain disease, is permitted.  
• For brain and thoracic radiotherapy (only to control symptoms), a 7- to 10-day study drug 
washout period before the procedure and 1 week period after the procedure before restarting study drug(s) is advised. 
• All radiotherapy related toxicities should be managed and ideally resolved before 
restarting  study drug(s). 
• Investigators should consider the radiotherapy when assessing causality if there are any localized AEs following the procedure. 
• If any lesions (including brain or thoracic disease) are  asymptomatic, then radiation 
would not be permitted. 
 